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Abstract 
Background: Chronic Kidney Disease (CKD) can be associated with many poor 
outcomes. Studies are required to assess gaps in care and the potential for 
improvements. Research is needed to determine the optimal process of care for CKD. 
Methods: I) A multi-centre Canadian prospective survey examined patient' s clinical 
status as they initiated dialysis. 2) A case-control study of incident dialysis patients 
evaluated clinical outcomes of patients previously exposed to formalized 
multidisciplinary clinic programs versus standard nephrology care. 3) A prospective 
multicentre Canadian cohort study of patients initially referred to nephrology with 
measured or estimated glomerular filtration rate less than 50 mL/min/1.73m2 evaluated 
patient status at referral , and nephrology intervention at first encounter. 
Results: 1) Canadian patients commencing dialysis in 1998-1999 appeared to be doing so 
in relative concordance with published guidelines with respect to timing of initiation. 
Despite an increased awareness of kidney disease, a substantial number of patients 
continued to commence dialysis without previous care by a nephrologist. Of those who 
were seen by nephrologists, clinical and laboratory parameters are suboptimal according 
to current guidelines. 2) Despite equal and long exposure to neplu·ology care prior to 
dialysis, there appeared to be an association of survival advantage for those patients 
exposed to formalized clinic care in addition to standard nephrologist follow-up. 3) CKD 
patients continued to have their first encounter with a nephrologist late in their disease 
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course. Information on prior evaluation was incompletely transmitted to the 
nephrologist. There appears to be room for improvement in evaluation and treatment at 
the first nephrology encounter. 
Conclusions: CKD care appears to be sub-optimal. Multidisciplinary clinics may play a 
role in improving outcomes. Further research is needed to address this care model. 
Ill 
Acknowledgements 
I would like to thank everyone who supported me during my graduate program. 
I am especially gratefully to Drs. Brendan Barrett and Adeera Levin for their assistance 
and guidance with this work and with my career. 
Drs Patrick Parfrey, John Harnett, Sean Murphy and Alan Goodridge have also assisted 
and supported me immensely. 
I would also like to acknowledge the many other colleagues and staff (especially at the 
Patient Research Centre, Health Sciences Centre, St. John' s and at St Paul 's Hospital, 
Vancouver) who have collaborated with me on the work contained herein. 
My sincere thanks to my friends-especially Dr Pamela Pike. 
And of course Sarah Mathieson 
I must also thank Laura Lucas and Charlene Smith for their administrative assistance. 
Work for this thesis has been funded by the Kidney Foundation of Canada through a 
Biomedical Research Fellowship held by me. Chapter 2 was supported in part by 
unrestricted educational grants from Janssen-Ortho Inc. and Baxter Canada. Chapter 4 
was also funded by the Kidney Foundation of Canada through two Biomedical Research 
Grants (held by Dr Adeera Levin and Dr Brendan Barrett) and co-funded with matching 
unrestricted grants from Ortho-Biotech and Baxter, Canada. None of the sponsors had 
any involvement in the design, implementation, analysis, interpretation or reporting of the 
work. 
iv 
For my Mother 
v 
Table of Contents Page 
Abstract 
Acknowledgements 
List of Tables 
List of Figures 
Overview 
11 
IV 
Vll 
Vlll 
Chapter I: Review- The Role of the Chronic Kidney Disease (CKD) Clinic 5 
1.1 Introduction 6 
1.2 Overview of CKD Clinic 12 
1.3 Key Goals of CKD Care 15 
1.4 Preparation for Kidney Replacement Therapy 28 
1.5 Clinic Logistics 33 
1.6 Other Studies 44 
1. 7 Conclusion 46 
Chapter 2: Canadian Survey of Clinical Status at Dialysis Initiation 1998-99: 47 
A Multicentre Prospective Survey 
2.1 Introduction 47 
2.2 Patients and Methods 48 
2.3 Results 51 
2.4 Discussion 58 
Chapter 3: The Short and Long Term Impact of Multi-Disciplinary Clinics in 63 
Addition to Standard Nephrology Care on Patient Outcomes 
3.1 Introduction 63 
3.2 Patients and Methods 64 
3.3 Results 68 
3.4 Discussion 75 
Chapter 4: Evaluation and treatment of CKD patients before and at their first 81 
Nephrologist Encounter in Canada 
4.1 Introduction 81 
4.2 Methods 82 
4.3 Results 88 
4.4 Discussion 106 
4.5 Addendum 110 
Chapter 5: Conclusion 112 
References 116 
VI 
List of Tables Page 
Table 1.1 Five Stages of Chronic Kidney Disease 10 
Table 1.2 Risk Factors for Cardiovascular Disease: As CKD progresses there is 21 
a parallel evolution of risk factors from traditional to those characteristic of 
chronic uremia 
Table 1.3 Example of a Protocol for Follow-up I Blood Work Intervals 42 
Table 2.1 Summary Demographics and Status at dialysis initiation in those 53 
patients known and not known to a nephrologist for greater than 3 months 
Table 2.2 Symptoms at Dialysis Initiation 54 
Table 3.1 Demographics at Dialysis Initiation. All patients known to 70 
Nephrologist for > 3 Months 
Table 3.2 Laboratory data (mean ± standard deviation) at dialysis start, 6 and 71 
12 months post dialysis 
Table 4.1 Demographic and Clinical Data for Patients with CKD 90 
at the Time of First Referral to Nephrologists 
Table 4.2 Referral of CKD Patients to Nephrologists in Canada 92 
Table 4.3 Prevalence of Cardiac Disease, Cardiac Risk Factors and CKD 95 
Complications at First Nephrology Encounter 
Table 4.4 Reported Symptoms At First Nephrology Encounter for Patients 96 
With Cardiac Disease 
Table 4.5 Laboratory Evaluation 99 
Table 4.6 Patient Medication Profile Before and After first Encounter By 102 
Nephrologist 
Table 4.7 CKD resource availability and utilization at first encounter 105 
VII 
List of Figures Page 
Figure 1.1 Care goals and Elements of CKD Programs. EOL, End of Life. 9 
KRT, Kidney Replacement Therapy 
Figure 1.2 Integration of care over the progression of CKD (Longitudinal 39 
Care) and between other caregivers (Parallel Care). 
Figure 1.3 An example of a protocol for anemia management that may guide 43 
therapy by physician or specialized nurse 
Figure 2.1 Abbreviated MDRD Study Equation estimating glomerular 50 
filtration rate 
Figure 2.2 Symptoms at dialysis start 55 
Figure 2.3 Age group differences in status at dialysis start 56 
Figure 2.4 Comparison of diabetics and non-diabetics patients 57 
Figure 3.1 Kaplan-Meier survival after starting chronic dialysis therapy 73 
Figure 3.2 Risk of death according to multivariate Cox-Proportional hazards 74 
modeling 
VI II 
Overview 
It has been well established that end stage kidney disease (ESKD) is associated with 
many poor outcomes such as premature death and poor quality of life [I , 2]. As such, 
there have been significant research achievements made to address these areas for 
dialysis patients. However, it has become increasingly clear that interventions to improve 
outcomes should be targeted at an earlier stage of kidney disease- mainly because the 
numbers of patients are greater at earlier stages, and the belief that intervention is too late 
once patients reach dialysis [3-6]. 
The term Chronic Kidney Disease (CKD) attempts to encompass many disorders 
pertaining to the kidney. It includes mild disorders, such as kidney stones, to loss of so 
much kidney function (usually estimated by measuring creatinine in a patient's serum) 
that dialysis is required to sustain life. Although some patients come to require dialysis 
because their kidneys fail quickly, most patients reach dialysis via CKD-especially 
related to diabetes or high blood pressure. However, having CKD does not necessarily 
indicate an inevitable progression. In fact, these patients also have a significant burden 
of comorbid disease and are more likely to die from cardiovascular disease before their 
kidney function deteriorates to the point where they require dialysis [7]. A challenge for 
health care providers is that CKD is mostly an asymptomatic disease whereby patients 
present for care at different points along the spectrum of kidney function level. Overall, 
the goal for better health care must focus on identification of CKD, slowing progression 
to dialysis and preventing co-morbidity and death. 
The first step in improving care using evidence-informed medicine is documenting 
current practices and outcomes. This allows distinction between what aspects of care are 
being done well versus where improvement is needed. After problems are identified, 
hypotheses about how to address care gaps may be generated and subsequently tested. 
This thesis will focus on areas where CKD care can be further optimized, and highlight 
the potential role of multidisciplinary clinics. 
The first chapter of this thesis will review the published data in relation to the above 
concerns. Having been written for this thesis, it was subsequently published as a book 
chapter [8]. This chapter will describe CKD as an important health problem, key goals of 
care, and the evidence on which these goals are founded. It will also describe the 
principles of chronic disease management and a model of integrated multidisciplinary 
team-based care focused on these goals. To complete the chapter, ongoing and future 
clinical trials are also reviewed. 
Further chapters will consist of my work using data from Canadian studies in which I 
have been involved. This work has also been published [9-11] in peer reviewed journals. 
My specific roles in Chapter 2 was data interpretation and co-writing the manuscript 
while my specific roles in Chapters 3 and 4 were collaborating on the design of the study, 
data collection, data analysis and interpretation and co-writing the manuscript. 
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For the purposes of this thesis, these subsequent chapters are organized to examine CKD 
care at different stages along the disease course as follows (GFR denotes Glomerular 
Filtration Rate, an estimate of kidney function): 
GFR 
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Before beginning to address any potential concerns it was important to document the 
then-current (1998-1999) clinical practice with respect to chronic kidney disease (CKD) 
care- the main questions were: is there a need for better care of CKD patients in 
Canada? What aspects of care have room for improvement? The main objective of 
Chapter 2 was to improve the understanding of the then-current Canadian nephrology 
practice. It focuses on whether patients are prepared for dialysis when they need to start, 
what are their metabolic parameters at initiation, and whether patients were referred to 
nephrologists beforehand. The findings presented in Chapter 2 indicate that patients 
commencing dialysis in Canada during that period appeared to do so in relative 
concordance with published guidelines with respect to timing of initiation. However, a 
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substantial number of patients commenced dialysis without previous care by a 
nephrologist and of those who were seen by nephrologists, clinical and laboratory 
parameters were suboptimal according to guidelines at the time. Thus, this survey served 
as an important baseline for future study and comparisons. 
Chapter 3 examines whether multidisciplinary clinics might have a role in care for 
patients with CKD by evaluating the outcomes of patients exposed to formalized multi-
disciplinary clinic (MDC) programs versus standard nephrologist care. The hypothesis is 
that MDC programs are able to better care for CKD patients prior to dialysis leading to 
better survival and metabolic parameters. The study findings indicate that despite 
prolonged exposure to nephrology care prior to dialysis, there appears to be an 
association of better survival following initiation of dialysis between those exposed to 
pre-dialysis formalized multidisciplinary clinic care. Thus, the data suggest that 
knowledge of a patient's status at the time of dialysis start can be important for predicting 
future clinical outcomes. To address this, the Canadian Care Prior to Dialysis (Can-Care) 
study was designed [11]. 
Chapter 4 discusses prospectively collected data on care earlier on in the course of CKD. 
It uses data from the Can-Care study and describes 1) characteristics of patients at first 
nephrology encounter for CKD in Canada, 2) the evaluation for cardiac risk factors, 
cardiac diseases and CKD complications and their management prior to the encounter, 3) 
changes in management initiated by nephrologists at first encounter, and 4) the 
availability and use of allied health professional services for CKD care. These data help 
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to identify opportunities for improvement in CKD care both before and after involvement 
of nephrologists. The study findings indicate that, in general, Canadian nephrologists 
tend to encounter CKD patients referred at a late stage in the disease (Stage IV CKD), 
and information on prior evaluation by other physicians is incompletely transmitted to the 
nephrologists. In addition, there appears to be room for improvement in the evaluation 
and treatment by nephrologists at the first nephrology encounter. 
A final note- I have decided to leave the previously published papers intact within their 
respective chapters. This means that the conclusions for each paper remain at the end of 
each chapter (versus placing them all at the end of the thesis). The final chapter will 
summarize what has been discussed. 
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Chapter 1: Review - The Role of the Chronic Kidney Disease Clinic 
Previously published as: Curtis BM & Levin A. The Role of the CKD Clinic. Section A 
Chapter 5. Chronic Kidney Disease, Dialysis and Transplantation. Second Edition, A 
Companion to Brenner & Rector's The Kidney. Edited by BJG Pereira, M Sayegh & P 
Blake. Elsevier Saunders 2004 pp. 71-85 
1.1 Introduction 
The purpose of this chapter is to outline the structure and function of a clinic-based 
approach for the comprehensive care of patients with chronic kidney disease (CKD) and 
describe some of the potential utilities of such a clinic. The described structure and 
function may serve as a template for the future development of such clinics. To ensure a 
context for such a clinic, the evidence and rationale supporting this concept is reviewed. 
Unlike the paradigm for care of those with diabetes [12, 13], or more recently for heart 
failure [ 14-18], the role of a clinic facilitating the care of patients with CKD has not been 
as clearly defined. Thus, data to support the concept and implementation are relatively 
scant, much being drawn from logical arguments as well as from experience with other 
chronic diseases. 
Kidney Disease Is an Important Health Care Concern 
The burden of disease and the growing population of patients with end-stage renal 
disease (ESRD) remain exceedingly high. In the United States a diagnosis ofESRD may 
impart more lost life years than prostate or colorectal cancer [1]. As of2001 in the 
United States, there were over 290,000 patients on dialysis and over 15,000 patients with 
kidney transplants [2]. Population studies such as the NHANES III cross-sectional 
survey of 29,000 persons revealed that 3% of people over age 17 had elevated creatinine 
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[ 19]. It is estimated that by 2030, the number of patients with ESRD may reach 2.24 
million [2]. Furthermore, the direct cost of caring for a patient on dialysis can cost over 
$50,000 (U.S.) annually [20, 21]. 
Kidney Disease Is Largely Due to Chronic Disease 
In North America CKD is largely due to diabetes and hypertension [2], both relatively 
easy to identify and treat with evidence-based interventions. The NHANES III survey, 
for example, showed that an elevated creatinine was more common in people with 
hypertension [19] . Furthermore, clinical trials and prospective cohort studies have 
identified risk factors associated with accelerated loss of kidney function. In patients 
with CKD secondary to diabetic, glomerular and hypertensive/vascular diseases, the 
strongest predictors of more rapid progression are hypertension, especially systolic [22-
30], and the degree and/or persistence of proteinuria [31-34]. 
Historically, the focus of nephrology delivered CKD care was to coordinate placement of 
vascular access, to attend to uremic symptoms and complications, and to provide dialysis. 
However, the focus has changed; not only is it increasingly recognized that the majority 
of patients with CKD do not progress to ESRD due to varying rates of progression [27, 
33] and competing risks for death [7], but also conditions associated with CKD itself, 
such as anemia and malnutrition, impart significant morbidity. Moreover, there is now a 
greater appreciation of the epidemiology of the disease, which has led clinicians to 
understand that the major competing risk for dialysis therapy was death from 
cardiovascular disease (CVD). Evidence has accumulated regarding the need for more 
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proactive care and institution of strategies to delay progression. Thus, the focus of CKD 
care has broadened to include CVD risk reduction, in addition to or concomitant with, 
reducing the progression kidney decline [35]. As our understanding has grown of the 
pathophysiology of kidney disease, and CVD within the CKD population, it has become 
clearer that the treatment and care options are increasingly complex. In addition, it was 
logical that identification and intervention in the population with earlier stages of CKD 
would provide the greatest opportunity to reduce morbidity and mortality. 
Goals ofTherapy 
The goals of therapy (figure 1.1) are to (I) delay progression of CKD, (2) delay I treat 
known CVD comorbidities, (3) manage uremic complications (such as anemia, mineral 
metabolism, nutrition, blood pressure), (4) ensure dialysis modality choice and timely 
placement of access for dialysis or assessment for possible transplant, and (5) initiate 
timely kidney replacement therapy, including preemptive transplantation where feasible. 
Each of these goals requires education of patients and caregivers, as well as 
communication between them, and co-management by different caregivers within 
medicine, including allied health professionals. With the one aim to maintain health, it is 
essential that the structure of the clinic reflect all goals and the demand for 
communication and investigation, to ensure success. 
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I 
Delay 
Care Goals and Elements 
of CKD Programs 
Early detection 
1- Treat 1- Manage 
Progression Co-morbidities Complications 
Prepare for 
KRT or EOL 
Education Patient independence Communication Tools 
Longitudinal follow-up of complex condition by trained interdisciplinary team 
Figure 1.1 Care goals and Elements ofCKD Programs. EOL, End ofLife. KRT, Kidney 
Replacement Therapy 
Staging and Terminology for CKD and Impact on Need for Coordinated Care 
In 2002 the National Kidney Foundation sponsored Kidney Disease Outcomes Quality 
Initiative (K/DOQI) published guidelines targeting earlier evaluation and intervention in 
patients with CKD [36]. Using evidence-based review, the cornerstone of the working 
group was the establishment of five stages of kidney disease (Table 1.1 ). Importantly, 
the classification system focused on estimated glomerular filtration rate (GFR) rather 
then serum creatinine levels alone, because use of serum creatinine alone may lead to 
overestimation or underestimation of kidney function in those with low (i.e., elderly, 
women) or high (i.e., muscular males, blacks) muscle mass, respectively. The new 
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system based the classification not only on severity of kidney function decline, but also 
on the presence of conditions associated with the kidney disease, such as proteinuria and 
hypertension. In attempting to clarify the historic terms, which are confusing and 
sometimes misleading (pre-dialysis, progressive renal disease, progressive renal 
insufficiency), this new definition and classification system is an important tool, which 
aids in the understanding of CKD and will help standardize its definition. A universal 
language or terminology will facilitate knowledge acquisition by the medical community, 
patients, and public bodies and improve research clarity and applicability. 
Staging of Chronic Kidney Disease 
Stage GFR Description (ml/min/1.73 m2) 
1 > 90 Kidney Damage With Normal or t GFR 
2 60-89 Kidney Damage With Mild .l, GFR 
3 30-59 Moderate .l, GFR 
4 15- 29 Severe .l, GFR 
5 < 15 or Kidney Failure (or dialysis) 
Table 1.1 Five Stages of Chronic Kidney Disease [36] 
The estimates of populations with CKD that were generated from the new classification 
system, and the NHANES population database, have helped identify the large burden of 
CKD that potentially exists in the community. The focus on earlier identification will 
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result in increased referrals for diagnosis, care, and follow-up that will overwhelm current 
nephrology resources, thus the need to create the appropriately structured care delivery 
systems described herein and to educate other health care providers in CKD care. 
Referral 
Late referral to nephrology has been recognized as a problem for many years, because it 
is associated with increased cost [5, 37-39]. Published recommendations emphasize 
timely referral to maximize potential gains from involvement of specialized nephrology 
teams [ 40]. The appropriate time for referral to a nephrologist is debatable for many 
reasons, including: (1) other physicians should be capable to manage earlier stages of 
CKD, (2) estimated high numbers of patients overwhelm current nephrology resources, 
and (3) many patients with early stages ofCKD may not progress. Nonetheless, a 
minimum recommendation would be for referral at GFR levels of less that 60 
mL/min/1 . 73 m2 if the primary caregiver cannot identify the cause of the disease or 
requires help in the management of the disease. All patients with GFR Jess than 
30mL/min/1.73 m2 should be seen by a nephrology team in order to ensure adequate 
psychological and clinical preparation for kidney replacement therapy [ 40, 41], unless the 
patient is of an age or has a condition that leads them to not consider chronic dialysis. 
The new CKD staging system focused on GFR estimation should reduce some of the 
problems of late referral due to misinterpretation of serum creatinine values. 
II 
1.2 Overview of CKD Clinic 
Philosophic Basis 
Clinics for the care of CKD should be based on the fundamental principle of ensuring the 
delivery of longitudinal, complex care to a large diverse group of individuals. This 
requires that the structure of the clinic and services offered optimize communication 
within and between individuals, including the patient and other physicians and medical 
teams. 
Role of Multidisciplinary Clinics 
The importance of early referral to nephrologists is not disputed [ 40], because 
identification of the myriad of abnormalities and plans for their treatment may be best 
achieved in consultation with a specialist. However, the ability of nephrologists "alone" 
to attend to the multiple and complex aspects of care in this patient group is debated [42]. 
As chapter 2 will show, a multicenter cohort of patients starting dialysis demonstrated 
that even those patients known to nephrologists for greater than 3 months have 
suboptimal care. In this study, one third did not have permanent access ready for dialysis 
initiation, mean hemoglobin was 94 g/L, and mean albumin was below 34 g/L [9]. In 
another multicenter study of patients with CKD followed by a nephrologist, the majority 
of patients had blood pressure over recommended targets, and only 50% were taking 
angiotensin converting enzyme (ACE) inhibitors [43]. While there are undoubtedly 
patient and compliance factors that explain why patients with CKD under the care of 
nephrologists do not have optimal care, it is also probable that patients were not provided 
the appropriate elements of care. It is important to note, however, that it was these 
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studies and others that contributed to the recognition of the importance of CKD care and 
lack of attention to it. 
Given the multiplicity of goals of CKD care, the complexity of treatment options, and 
educational needs, it is clear that a team of individuals will be required. Treatment 
targets, such as blood pressure, may be reached by involving expert nurses, pharmacist, 
or other members of the team in conjunction with the physician [44]. Thus, a team 
approach with well-defined roles, responsibilities, and objectives appears to be both 
logical and practical. Improved patient care and outcomes due to a multidisciplinary 
team clinic have been demonstrated in disciplines such as diabetology [12, 13, 45], 
cardiology [14-16, 18, 46], rheumatology [47-49] , and oncology [50]. Similarly, 
compared to standard care by a nephrologist alone, there is evidence of benefit of a 
multidisciplinary care (MDC) team approach in the care ofpatients with CKD [51-53]. It 
appears that outcomes can be improved with protocol-based blood work, clinic visits, and 
education. This requires involvement of a patient educator, dietitian, social worker, and 
physician. 
There have been few randomized, controlled trials of case management in CKD. The 
first, published by Harris and associates [54] did not show a benefit to case management 
in CKD. However, the intervention in that study was limited to written suggestions made 
to primary care physicians and the assigned clinic patients did not receive any specific 
treatment for anemia, mineral metabolism, or preparation for dialysis I transplant. Failure 
to show a benefit in the Harris study may well have been due to the failure of individual 
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primary care physicians (PCP) to implement the recommendations from the clinic. Given 
that PCPs are inundated with protocols and guidelines for the management of numerous 
chronic conditions, it is unrealistic to expect them to be able to fully attend to the many 
complex issues of advancing CKD. 
A more recent Australian randomized control trial [55] compared a physician-supervised, 
nurse driven multiple risk factor intervention clinic with conventional care. The clinic 
focused on dyslipidemia, hyperhomocysteinemia, hypertension, anemia and 
hyperphosphatemia control in patients with stage 4 or 5 CKD. Although the study did 
not show improvements in the primary outcome measures, atheroma burden (via carotid 
initmamedia thickness) and endothelial function (via brachial artery reactivity), the 
intervention group showed significant improvements in serum lipid and blood pressure 
control. 
Structure and Definition of Multidisciplinary Clinics 
These definitions help to clarify the various possible variants of a multidisciplinary team. 
It allows the determination of what type of resources are currently available and may help 
in the interpretation of clinical studies so that similar types of clinics can be compared. 
Clinic structures can be categorized as follows with respect to multidisciplinary teams: 
Formal Multidisciplinary Team: Nurses, nurse educators, dietitians, social workers, and 
physicians allied in a formal relationship, who interact with the patient and each other 
defines a multidisciplinary team. Although it is recognized that there are a number of 
different configurations due to funding and local health care system issues, for the 
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purpose of definition, this team is readily identifiable as dedicated (part time or full time) 
to CKD care, and may or may not have team rounds or meetings to discuss patient care. 
Informal Multidisciplinary Resources: Nurses, social workers, dietitians, and physicians 
associated with the kidney team to whom patients are referred may constitute informal 
resources. In such a schema, patient access is dependent on individual patient needs, and 
the group of individuals may or may not interact as a team or be necessarily dedicated to 
the longitudinal follow-up of patients. Each team member is able to interact with the 
patient on a regular basis as necessary, but no coordination with other team members is 
inherent to its structure. 
No Multidisciplinary Team: Nurses, social workers, and dietitians may or may not be 
available to the patient. There is no team structure or function. 
1.3 Key Goals of CKD Care 
The following section describes the key goals of comprehensive CKD care, citing 
evidentiary basis as appropriate for the described strategies. This includes diagnosis, 
education, delay of progression, identification and treatment of co-morbidities associated 
with CKD and of complications of CKD. As well, the institution of primary prevention 
strategies, including vaccination programs and the preparation of patients for renal 
replacement therapy as appropriate, will be discussed. The goals described are 
comprehensive and complex, thus the need for a protocolized structured delivery system, 
such as a formal clinic. 
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Diagnosis 
The first goal of the nephrology clinic medical staff should be to attempt to establish or 
confirm a diagnosis and to determine the rate of progression of kidney disease. The 
nephrologist should ensure that appropriate tests have been undertaken to establish a 
diagnosis. Kidney biopsy or imaging may be helpful [ 40] , especially to rule out any 
potentially treatable or reversible etiologies such as rapidly progressive 
glomerulonephritis or obstruction. In early visits, reversible causes of kidney disease 
should be sought, even if a chronic etiology is suspected, especially if there has been a 
rapid decline in kidney function. In addition to diagnostic tests, review of current 
medications to ensure the absence of nephrotoxic medications is prudent. Further 
workup includes a review of family history and a search for systemic disease, including 
diabetes, vascular disease, connective tissue disorders, infections, and malignancy. 
Several contributory factors may coexist. The extent of comorbidities, especially the 
commonly associated vascular diseases [56] should be continually assessed. Although 
established kidney disease may progress even if the original cause is removed [57], 
similar interventions that can slow loss of kidney function may prevent cardiovascular 
complications. Potentially harmful interventions, such as iodinated intravenous contrast 
dye, must be reviewed with the patient so that educated decisions may be made regarding 
their use. 
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Education 
Patient education and awareness are an integral component of the clinic. Education is 
important from a decision-making perspective as well as to alleviate fear and 
psychological suffering. Educated patients are more likely to take an active part in their 
care, with better outcomes noted in other chronic diseases [58-60]. Ideally, involvement 
of family members or other support network individuals should be encouraged. The 
clinic environment can provide a set of resources as well as sessions related to patient 
education. Minimal education should include the following, presented at the appropriate 
stages of CKD: 
• Explanation of normal kidney function, blood pressure, and laboratory test results 
and their significance. 
• Explanation of specific disease conditions, symptoms, and complications of CKD. 
• Dietary teaching and diabetes education, if appropriate. 
• Ensuring that patient understanding of medications is adequate. 
• Discussions about vein preservation (blood taking and blood pressure) 
• Erythropoietin hormone therapy teaching, including: importance of anemia and 
its treatment; ensure patient understanding of dose changes; warning of the side 
effects of iron therapy; self-administration or local administration by PCP or 
community nurse; and provision of educational materials to PCP. 
• Discussion of choices for treating ESRD, including conservative therapy, 
hemodialysis, peritoneal dialysis, and transplant. 
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• The education effort can be augmented with pamphlets or video materials. Using 
the principles of adult learning, regular reinforcement of the key messages should 
be incorporated into the education program. 
Delay of Progression 
The cornerstone of CKD care is to delay progression of kidney disease and, thereby 
reduce complications related to kidney failure. The evidence is relatively consistent in 
citing that interruption of the renin-angiotensin system (RAS) is a key component to 
delaying progression. Control of hypertension and reduction of proteinuria are important 
consequences of RAS interruption and are described more fully later. 
Hypertension Treatment 
Blood pressure should be based on the average of two or more seated readings on each of 
two or more office visits [ 61]. There is substantial evidence to support the optimal and 
target blood pressure of less than 130/80 mmHg in patients with established kidney 
disease, as suggested in the guidelines of the Seventh Joint National Committee for 
Prevention, Detection, Evaluation and Treatment ofHigh Blood Pressure [27, 61-64). 
The goals are to reduce the rate of decline of kidney function [ 65-67] and decrease 
cardiovascular events and mortality. The recommended target blood pressure for patients 
with proteinuria greater than 1 g/day is less than 125/75 mmHg [64]. This is based on 
evidence of slower progression of kidney failure at this level of blood pressure in a large 
randomized trial, which showed the greatest gain in those with the most proteinuria [27, 
28]. Patients with kidney disease often need between three and four different 
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medications in addition to lifestyle modification in order to achieve this goal [66]. ACE 
inhibitors, angiotensin receptor blockers, P-blockers, calcium channel blockers, and 
diuretics are key drug classes for achieving blood pressure control [27, 68-70]. 
Proteinuria Reduction 
Patients with CKD and persistent proteinuria of greater than 3 g/day may progress to 
requiring dialysis or transplant within 2 years [22, 71 , 72]. A number of large, 
randomized, controlled trials demonstrated the efficacy of ACE inhibitors in slowing 
progression of kidney disease, reducing proteinuria, and also in regressing left ventricular 
hypertrophy [73-79]. As some of these trials were placebo-controlled, it is difficult to be 
sure that the benefit was drug specific and not just due to blood pressure lowering. 
Nevertheless, follow-up studies suggest that long-term ACE inhibition, as a component 
of blood pressure therapy, can be associated with stabilization and even improvement of 
kidney function [79]. Prophylactic use can also be justified in type II diabetes, because 
ACE inhibition preserved kidney function for over 6 years in normotensive type II 
diabetics without microalbuminuria [80]. More recently, the use of angiotensin receptor 
blockers (ARB) have been shown to reduce the time to doubling of serum creatinine, 
reduction of proteinuria, and time to dialysis [ 68, 69, 81]. All of these recent studies have 
been preformed in diabetics. Mann and associates have demonstrated the utility of ACE 
inhibitor use in patients with established CVD, diabetes plus one risk factor and kidney 
disease, in a subanalysis of HOPE [82]. More recently, a trial demonstrated that dual 
blockade of the renin-angiotensin system with both an angiotensin-converting enzyme 
inhibitor and an angiotensin- II receptor blocker (vs. monotherapy and placebo) may offer 
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additional renal and cardiovascular protection in type II diabetic patients with diabetic 
nephropathy [81]. 
Management of Comorbidity: Secondary Prevention 
Cardiovascular Disease 
CKD is a risk factor for vascular events and death [83, 84]. Creatinine values as low as 
130 to 150 ).lmol/L confer a threefold risk of death within 8 years [83]. Cardiovascular 
death is 25 times as common as death due to kidney failure in type II diabetics with 
microalbuminuria [85]. The prevalence of cardiomyopathy, symptomatic heart failure, 
and symptomatic ischemic heart disease is very high at dialysis initiation [86]. This 
suggests that the later stages of CKD are a state of high cardiac risk. 
Reversible cardiac risk factors, identified in these earlier stages, persist following entry to 
dialysis. Left ventricular hypertrophy (L VH) occurs in the CKD population, and its 
prevalence is inversely related to the level of declining kidney function [87]. Anemia and 
hypertension are also risk factors for progressive LV growth [87]. In kidney transplant 
recipients, a model of CKD, hypertension is a risk factor for LV growth, de novo heart 
failure, and de novo ischemic heart disease [88-90]. In addition, anemia predisposes to 
de novo heart failure [90] while dyslipidemia and smoking are risk factors for ischemic 
heart disease [91]. 
The National Kidney Foundation convened a task force in 1997 to specifically examine 
the epidemic of CVD in chronic kidney disease [92]. With a focus on decreasing death 
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rates via strategies for prevention of disease, the task force considered whether strategies 
learned from the general population are applicable to patients with CKD. Recognized 
traditional risk factors identified in the general population include diabetes, hypertension, 
smoking, family history of coronary disease, male gender, older age, high low-density 
lipoprotein cholesterol, low high-density lipoprotein cholesterol, physical inactivity, 
menopause, and psychological stress (Table 1.2). 
Risk Factors for Cardiovascular Disease 
Traditional 
Diabetes 
Hypertension 
History of smoking 
Family history of coronary disease 
Male gender 
Older age 
Dyslipidemia 
Proteinuria 
Physical inactivity 
Menopause 
Psychological stress 
Uremic 
Hemodynamic overload 
Anemia 
Malnutrition 
Hypoalbuminemia 
Inflammation 
Prothrombotic factors 
Hyperhomocysteinemia 
Increased oxidative stress 
Divalent ion abnormalities 
Vascular calcification 
Hyperparathyroidism 
Progression of CKD 
Table 1.2 Risk Factors for Cardiovascular Disease: As CKD progresses there is a parallel 
evolution of risk factors from traditional to those characteristic of chronic uremia. 
As CKD progresses, additional risk factors related to chronic uremia also emerge. 
Excess cardiac risk may also be due to hemodynamic and metabolic perturbations, 
including fluid overload, anemia, malnutrition, hypoalbuminemia, inflammation, 
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dyslipidemia, prothrombotic factors, hyperhomocysteinemia, increased oxidative stress, 
divalent ion abnormalities, vascular calcification, and hyperparathyroidism [93, 94]. 
Patients with kidney failure therefore require assessment and therapy for vascular disease 
and associated risk factors. It should be noted that many risk factors for CVD are also 
associated with the risk of progression of chronic kidney failure [56]. Thus, risk factor 
reduction strategies used to prevent CVD in the general population can be applied to 
patients with CKD and may slow the progression of kidney disease as well [56]. It 
remains unclear whether a raised serum creatinine is a marker for more severe 
hypertension, diabetes mellitus, and vascular disease, which causes death, or a marker for 
some intrinsic property of kidney disease, which accelerates CVD. However, some 
factors thought to induce cardiac risk are more peculiar to kidney disease (anemia, 
hypoalbuminemia, dyslipidemia), and may be amenable to intervention. 
Anemia 
It has become increasingly evident that anemia is an important predictor of morbidity and 
mortality in the dialysis population [6, 95, 96]. It is associated with ischemic heart 
disease, left ventricular hypertrophy, and impaired quality oflife [95-97]. Correction of 
anemia in CKD improves physical function, energy, cognitive function, and sexual 
function [95, 98-10 I]. 
Treatment of anemia with erythropoietin is effective. Studies are currently underway to 
determine whether early initiation of therapy among individuals with earlier stages of 
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CKD is effective in preventing CVD, decreasing progression of kidney disease, or 
improving QOL [96, 102, 103]. There is evidence to suggest that iron supplementation in 
early kidney disease is important to maintain erythropoiesis, and that erythropoietin 
therapy is needed to maintain hemoglobin levels. Specific targets for hemoglobin levels 
have not yet been determined, though levels between 100 and 125 g/L are the current 
recommended guidelines [11 , 95, 104, 105]. 
Mineral Metabolism 
There is evidence to support the efficacy of calcium and/or vitamin D supplementation 
for treatment of hyperparathyroidism [ 106-1 09]. Recommendations regarding target 
values for patients with earlier stages of CKD have been extrapolated from those for 
patients with ESRD. An approach that attempts to prevent hyperparathyroidism and its 
associated long-term complications is suggested. Phosphate reduction using dietary 
restriction, and inexpensive phosphate binders I calcium supplementation in those who 
have evidence of elevated intact parathyroid hormone (iPTH), and low normal calcium 
levels is reasonable. Vitamin D analogues are useful for those in whom PTH remains 
elevated despite calcium supplementation and phosphate restriction. Physiologic release 
of hormones is pulsatile and thus, intermittent oral vitamin D therapy is recommended. 
Unfortunately, evidence for the effectiveness of therapeutic strategies and for specific 
target levels of each of the variables mentioned above is not available for earlier stages of 
CKD. Adherence to the principle of prevention, combined with early identification of 
calcium, phosphate, and PTH abnormalities at early stages of CKD, should lead to 
minimizing hyperplasia of the parathyroid glands and the attendant metabolic 
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derangements. Future studies will need to address long-term targets and therapeutic 
strategies. 
Nutrition 
Malnutrition is common in patients with later stages of CKD. There is a strong 
association between decreased albumin and worse nutritional status, and adverse 
outcomes [98, 11 0-112]. Even small decreases in albumin are associated with increased 
mortality. Unfortunately, albumin is a late index of malnutrition and is a negative acute 
phase reactant. Acidosis is also a contributor to protein breakdown and mineral 
metabolism aberrations. Thus, assessment of nutritional status generally requires the 
expertise of a dietitian. 
Low protein diets have been extensively studied as a means to slow the progression of 
kidney disease, with mixed results. Meta-analyses and a large, randomized trial suggest 
that the impact may be slight [27, 113-115]. Optimal dietary protein intake is not clear 
[113] , and there is a potential for protein malnutrition. Appropriate nutritional counseling 
to avoid malnutrition, acidosis, and phosphate excess is important. There are extensive 
guidelines for assessment of nutritional status and dietary management proposed by the 
National Kidney Foundation [116]. Ensuring adherence to a prescribed diet is difficult 
and requires frequent, continuous input from dietitians. This becomes especially 
important as the patient approaches ESRD, since worsening malnutrition may become the 
principal indication to initiate dialysis. 
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Management of Comorbidity: Primary Prevention 
Primary prevention strategies are also important in the management of patients with CKD 
and may sometimes be overlooked due to the time-intensive management of conditions 
associated with uremia. Although it is not clear who should be mainly responsible for 
these issues (nephrologist versus family physician or other specialist), they will be 
discussed here because all these professionals can be part of the CKD patient' s team, and 
the nephrologist may be able to input expertise for this specific population. Vaccinations, 
use of aspirin and lipid lowering agents and other CVD primary prevention strategies, as 
well as diabetes control, smoking cessation, and lifestyle modification are important. 
This section briefly touches on these strategies in CKD patients. 
Vaccination 
Hepatitis B infection remains a concern in dialysis populations, and current 
recommendations are to vaccinate if appropriate. In addition, there are recommendations 
to vaccinate patients with CKD against pneumococcal infection and influenza, which are 
common sources of morbidity in patients with chronic illnesses. Vaccination programs 
have been less successful among CKD patients compared to the general population, both 
in terms of implementation and response to vaccine. Reasons for poor response include 
malnutrition, uremia, and generalized immunosuppressive state of patients with CKD. 
However, variations in vaccination dose and dosing schedule to increase response rates in 
dialysis patients have been tried with reasonable success, which could be implemented 
among patients at all stages of CKD. In general, patients with higher GFR levels are 
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more likely to respond with seroconversion to hepatitis Band other vaccines [117]. This 
reinforces the need to identify CKD early and provide comprehensive care. 
Aspirin 
The use of low dose aspirin should be considered to reduce the risk of subsequent CVD 
in patients with coronary artery disease or in those who are at high risk of developing 
coronary disease [92], which include most patients with CKD. Recommendations to use 
aspirin should take into consideration the individual patient' s risk of bleeding or other 
complications of aspirin. If there are contraindications to aspirin use, the use of other 
antiplatelet agents could be considered. 
Dyslipidemia 
There are no trials showing that treating dyslipidemia slows the progression of kidney 
disease. With respect to preventing cardiovascular disease in this population, post hoc 
analysis of the Cholesterol and Recurrent Events study [ 118] and the Anglo-Scandinavian 
Cardiac Outcomes Trial [119] suggested a benefit in patients mainly with stage 2 and 3 
CKD. Regarding lipid targets, the Heart Protection Study suggested benefit in treating 
patients with coronary disease, other occlusive arterial disease, or diabetes largely 
irrespective of initial cholesterol concentrations [120]. Until ongoing trials such as the 
Study of Heart and Renal Protection [121] answer the question of treating lipids 
specifically in CKD patients, current guidelines recommend an aggressive approach to 
lipid abnormalities in diabetics and other high-risk patients, which would include those 
with CKD [63, 122]. Thus, best practice would suggest following the guidelines of the 
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National Cholesterol Education Program Adult Treatment Panel II for initial 
classification, treatment initiation, and target cholesterol levels for diet or drug therapy 
[123]. 
Diabetic Control 
Optimal glycemic control in those patients with diabetes mellitus should be encouraged 
and facilitated with referral to a diabetes clinic if possible. Tight glucose control in both 
types I and II diabetes may prevent or stabilize the early stages of microvascular 
complications, including nephropathy [ 124, 125]. The impact seems to be sustainable for 
years [ 126]. However, diabetic control has not been shown to slow progression of 
advanced diabetic nephropathy. Furthermore, as kidney function deteriorated, diabetes 
management will require modification. 
Lifestyle Modification 
Smoking cessation is recommended for many reasons, including the possibility that it 
may slow Joss of kidney function [127, 128]. Obesity, poor diet, and sedentary lifestyle 
contribute to diabetes, hypertension, and vascular disease. Current recommendations are 
thus to achieve and maintain an ideal body mass index and moderate level of physical 
activity for 30 minutes per day for most days of the week [92]. 
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Rehabilitation 
Cost of kidney disease from loss of work and associated loss of QOL is substantial. 
Strategies to enable patients to remain working or return to work should be in place [53, 
129] and may involve referral to work retraining programs or occupational therapist, if 
available. 
1.4 Preparation for Kidney Replacement Therapy 
Preparation for kidney replacement therapy should be based on a good basic knowledge 
of kidney function, ideally a long process that begins well before the imminent need for 
initiation exists. Modality selection is done collaboratively with the tean1 and the 
patients, with an attempt to ensure that patients maintain independent care status and 
choose modalities that foster such independence. The appropriate timing of initiation of 
dialysis remains unclear, but it is certain that it must be individualized and must be based 
generally on a combination of low GFR, patient symptoms, and other factors. Close 
follow-up of patients at the later stages of CKD, with objective assessment of global 
functioning, permits appropriate timing of dialysis initiation. 
Modality Selection and Access Placement 
Modality selection is a decision for the informed patient. It is unknown whether 
peritoneal dialysis or hemodialysis imparts a survival advantage over the other, as neither 
randomized trials have been done nor is one feasible in the future. Transplantation is a 
medically and economically superior treatment [130] for kidney replacement therapy and 
is associated with higher quality of life. At any given time approximately 50% to 60% of 
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patients receiving dialysis are eligible for transplantation, but estimates are not available 
for those with earlier stages of CKD. Not all patients are eligible for transplantation, 
such as those with severe underlying illness. Preemptive transplantation, that is, before 
the need for dialysis, is generally possible for only those with an available live donor. In 
the United States, approximately 30% of transplants are from living donors, and a fifth of 
these are unrelated to the recipient. 
It is clear that for some people, contraindications to one ofthe modalities may exist; for 
example, extensive prior abdominal surgery may negate the possibility of peritoneal 
dialysis. Importantly, the patient's desire to undertake chronic dialysis must be closely 
explored, because there may be some with serious underlying illnesses who choose to not 
undertake renal replacement therapy. 
The option for kidney replacement therapy need to be reviewed with the patient, and 
access should be planned appropriately, if needed. The reality of how long it takes to 
decide on modality, get access placed, and let access mature should be stressed to 
patients, as should the possibility that the first access may not work. A perspective on the 
relative amount of time required to prepare for each of the options, including 
transplantation, should be provided. It should also be stressed that the presence of a 
working access (such as a functioning fistula) does not mean the patient has to start 
dialysis any earlier. A functioning, albeit unused, access only ensures that additional 
procedures, such as placement of a temporary catheter, might be avoided. 
29 
Lack of preparation for dialysis increases morbidity and cost [131-133]. Cost and 
morbidity implications of temporary catheter access are extensive. They include the cost 
of catheters, insertion fees, radiology tests, and costs associated with complications such 
as infection and thrombosis, as well as the pain, discomfort, and time of the patient. 
Planning for kidney replacement therapy should begin at least 6 months in advance of 
anticipated start. According to published guidelines [134], access should be created at 
GFR of approximately 20 to 25 mL/min in those who are anticipated to progress and who 
do not have reasonable chance for a preemptive transplant. Reasons for lack of access at 
dialysis start may include patient factors such as denial of inevitable dialysis, being too 
sick to undergo permanent access procedures, or late decision to undertake chronic 
dialysis. However, this may also reflect the CKD team's inability to predict dialysis start, 
lack of resources, or poor planning. Late recognition of CKD and late referral to 
nephrology contribute to the problem. In consultation with the patients and the clinic 
team, optimal timing around education, decision making, and access creation should be 
undertaken. 
Timely Initiation 
When to initiate dialysis is a complex decision that involves the consideration of many 
variables. There are some easily identified absolute indications for initiation [135] , 
however, debate exists with respect to ' timely" dialysis when these indicators are not so 
apparent. Indeed, since the 1970' s Bonomini has argued for initiation of dialysis before 
clinically significant markers of uremia appear. His studies suggested a positive 
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association between residual kidney function at dialysis initiation and clinical outcomes 
[Ill , 136-139]. Unfortunately, lead-time bias, patient selection, or referral bias may 
favor outcomes in the population of patients starting "timely" dialysis. Further 
complicating the issue is the lack of a tool to define where a patient is on the time-line of 
CKD, for both planning and comparison of study results. To date, there is no solid 
evidence regarding how "early" dialysis should be started for optimizing patient 
outcomes. 
Presently, two main indices for initiating dialysis for the treatment of kidney failure 
following progression of CKD are: (1) low GFR and (2) symptoms or signs of uremia, or 
evidence of malnutrition [ 140]. Despite the lack of firm evidence, the National Kidney 
Foundation guidelines, first published in 1997 and updated in 2000, recommend that 
patients should begin dialysis when the GFR falls below 10.5 mL/min/1. 73m2 
(approximately a Kt/V urea of2.0), unless edema-free body weight is stable or increased, 
the normalized protein nitrogen appearance (nPNA) rate is greater then or equal to 0.8 
gm/kg/day, and there are no clinical signs or symptoms of uremia. More recently, the 
Canadian Society ofNephrology has recommended that dialysis should be initiated when 
the GFR is less than 12 mL/min if evidence of uremia or malnutrition (nPNA < 0.8 
g/kg/day, or clinical evidence of malnutrition) exists. Despite these and other guidelines, 
when to initiate dialysis remains debatable. Overall, the key factor is to avoid 
commencing dialysis when the patient is so ill that education opportunities and the 
chances for maintaining independence are impaired. 
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Hemodialysis 
The goal is a non-traumatic start to hemodialysis care, and the CKD clinic staff should 
ensure the appropriate commencement of dialysis, including ensuring that patients have 
appropriate vascular access and are oriented to the hemodialysis unit. Schedules should 
be coordinated with appropriate team members in the hemodialysis unit, family members, 
and other medical professionals. The CKD clinic should send initial dialysis orders and 
transfer summaries to the hemodialysis unit. 
Peritoneal Dialysis 
Patients should be oriented to the peritoneal dialysis unit and staff. The role of the CKD 
clinic in organizing peritoneal dialysis catheter placement will vary from center to center. 
However, the timing, placement, and preliminary education should be done in concert 
with the peritoneal dialysis team. As in hemodialysis, specific orders and transfer 
summaries should be sent to the peritoneal dialysis unit and the training I initiating 
schedule coordinated with appropriate team members, family members, and other health 
professionals. 
Transplant 
As part of the educational process early in the course of CKD, the concepts of 
transplantation and living donation should be explored with patients and families. The 
CKD clinic working closely with the transplant assessment team can help determine 
eligibility for a transplant. Furthermore, a CKD clinic can facilitate preemptive 
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transplantation, which is generally only possible if the patient with CKD has an available 
living donor. 
Conservative Care 
Not all patients will desire or benefit from kidney replacement therapy; longer-term 
education, longer follow-up time, and an established relationship with CKD team 
members will facilitate making this choice. In these cases, the CKD clinic staff may be 
the first to be aware of the wishes of the patients and families, and other caregivers 
should be informed of these decisions. Once such a decision is made, end-of-life wishes 
should be formalized, in particular extent of resuscitation attempts, with appropriate 
consent and documentation. Resources to ensure appropriate supportive care short of 
dialysis should be mobilized, because much can be done to maintain a patient who 
chooses to not undertake chronic dialysis. The patient should have referral for home care 
and for palliative care when appropriate. Patients may benefit from remaining in the care 
of the CKD team as plans of care may require revision or the patient may change his 
mind. 
1.5 Clinic Logistics 
Services 
The CKD clinic would presumably exist within a health care system and society where 
the common goal is the health of the patients. Comprehensive care delivered in only one 
location is presumed to be beneficial. The frequency with which any individual patient 
accesses care is determined by the specific circumstances of the medical system, the other 
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physicians involved in patient care, additional comorbid conditions, as well as the 
specific stage of disease. The clinic should provide a wide range of services for patients 
with kidney disease, and their physicians, with the overall goals of: 
1. Ensuring patient and family understanding of kidney disease. 
2. Ensuring understanding of health care system I hospital and outpatient 
systems and services available to kidney patients. 
3. Identifying potential issues related to long-term patient management. 
4. Facilitating longitudinal and parallel care of patients with CKD. 
Key Components of the Clinic 
The clinic should ideally be an outpatient facility providing easy access to all facilities 
and personnel in one location. This permits familiarity with team members and access to 
ancillary services as needed. If also located in proximity to the hospital or dialysis 
center, it provides familiarity with the respective hospital services and locations. Non-
English patients should have interpreters provided and booked for entire duration of the 
clinic visit. It helps if interpreters are able to return with specific patients to facilitate 
continuity. An information package should be available and given out at the first visit, 
including an introduction to how the clinic works and various educational materials, 
including goals and expectations. Patients and families should also have an introduction 
to team members, and explanation of roles of responsibilities. Finally, the clinic should 
facilitate peer support for patients with CKD. 
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In addition to ongoing assessment of patient by the team through regular clinic visits, 
weekly multidisciplinary rounds should be organized to facilitate communication and 
develop or adjust plan of care. This will allow for comprehensive follow-up by nurses, 
clerical staff, and others and facilitate: 
• Bookings for tests (Ultrasound, CT Scans, etc.) and referrals to other specialists 
• Medication changes I tolerance, etc. 
• Reminders for appointments/blood work. 
• Follow-up of test results. 
• Liaison with laboratories and pharmacies. 
• Liaison with GP and other consultants, including palliative care team (in hospital 
or community). 
• Patients should receive education about kidney or kidney I pancreas transplant 
and screening for potential donors and referrals as appropriate. 
Individual Roles 
In order for any team to function, definition and clarification of roles of the individuals 
involved are important. Below are listed key roles and responsibilities for each of the key 
staff deemed important in the delivery of CKD care. The specifics may vary depending 
on local issues, but the principal roles need to be clearly defined. 
Nurse 
The CKD nurses function as case managers and facilitate care of patients, directly and 
through physician and team member liaison. Nursing support should be available 5 days 
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a week by telephone or in person to triage medical concerns, answer questions, and 
provide education or emotional support and referral to other team members or community 
resources. This should allow for ongoing collaboration and reevaluation with the patient, 
and facilitate changes in care plan with input from team members. A regular review of 
symptoms, medications, and monitoring of lab work results should occur, again 
responding to critical values by notifying physician, patient, and dietitian as necessary. 
The nurse should be able to liaise with family physicians, consultants, and other chronic 
disease clinics (e.g., diabetes, health heart, heart function clinic). 
Nurses should be able to implement protocols such as hepatitis screening and vaccination 
program or peri-angiogram protocols. Similarly, they should be able to arrange treatment 
and procedures such as intravenous iron and transfusions or arrange referral for dialysis 
access and follow-up care. If patients progress to kidney failure, then the nurse should 
ensure coordination of initiation of dialysis or referral for transplantation and transfer of 
relevant data to dialysis or transplant facility. Finally, they should coordinate services in 
remote setting for the convenience of patients. 
Dietitian 
Patients should receive individualized diet education and counseling regarding CKD, 
diabetes, and heart disease, from a dietitian knowledgeable about the nutritional 
abnormalities of CKD. The dietitian should review diet history, habits and nutritional 
health, and advise patient about food choices and meal ideas. There should be a periodic 
dietary review, including blood work, to help reach goals and to avoid malnutrition. 
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Social Worker 
Social workers may provide assistance with emotional and practical concerns of patients 
and their families, and assess emotional needs or potential issues that may arise, such as 
acceptance of kidney failure and end-of-life issues. The social worker should have a 
mechanism to liaise with psychiatry as needed . They also advocate on the patient's 
behalf to ensure maximum allowable benefit from available resources such as home 
support, financial assistance, employment I retraining, and housing, and may need to 
assist the patient with insurance issues, including referral to institutional financial 
counselors. 
Pharmacist 
If possible, pharmacy services should be available for initial medication review and 
follow-up. They may advise about medication costs, pill burden, and possible 
interactions. They may also provide education and support as needed. 
Clerical or Administrative Support 
Clinics should have a dedicated unit coordinator I clerical support worker. Their main 
role is to ensure that data and patient charts are maintained accurately. A paper I 
electronic chart should be established with complete information available and 
maintained with ongoing follow-up data. This will include data such as laboratory 
results, medications, and comorbidities. The coordinator is an essential component of the 
team as the organization of booking and coordinating appointments with other clinics, 
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consultants, diagnostics, and community resources and follow-up is essential. 
Additionally, they are integral for information and chart transfer to programs within the 
kidney programs such as dialysis or transplant clinic. They may also triage patient 
concerns with the team and have appointment reminders for patients. Finally, they 
should identify interpreter requests and book interpreters as needed. 
CKD Clinic Role in Longitudinal Care: Different Stages of CKD 
Given the current estimates of the CKD population (between 10 and 20 million in the 
United States), it is unlikely that the optimal resources described in this chapter are 
available to all patients with CKD. It is still debated whether a nephrologist must see all 
patients will early CKD, as it is not clear who will and will not progress. Although there 
is consensus that nephrologists and teams need to see the patients at least 6 months, and 
ideally 12 months, prior to dialysis start for access, there remains skepticism regarding 
the utility of nephrology input prior to that time. 
Although much has been learned about care of patients close to initiating dialysis, it is not 
known how to optimally care for patients in early CKD (frequency of visits, frequency of 
blood work, when to initiate "early" drug therapy, etc.). It seems reasonable that a 
"phased" approach is applicable. As outlined, the focus of the clinic must be adjustable 
from early disease detection and risk factor modification to preparing for kidney 
replacement therapy. Key at all phases would be communication and education between 
patients, medical caregivers, and allied health teams (figure 1.2). 
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Figure 1.2 Integration of care over the progression of CKD (Longitudinal Care) and 
between other caregivers (Parallel Care). 
One end of the spectrum is an early referral (stage I or II) and a broad plan outlined to 
another caregiver about goals of treatment of that caregiver to follow. Patients could be 
fam iliarized with the clinic and kidney disease at this initial period and then referred back 
to the clinic if the kidney function deteriorates, for further education and refinement of 
management plan. Both the patient and the other caregiver are informed that the clinic is 
available when needed for either informal consultation or formal evaluation. The other 
end of the spectrum is for the clinic to assume most of the care, if not all, surrounding 
issues pertaining to kidney disease and other issues such as diabetes management. In 
between, the clinic could do a formal initial evaluation and then arrange follow-up once 
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every year or so. To date there are no studies that have systematically evaluated the 
impact of different methods of care at earlier stages of CKD, though a number of trials 
are being planned. 
CKD Clinic Role in Parallel Care: Integrating with Other Caregivers 
An important issue in dealing with individual patients who are obtaining care in parallel 
locations (i.e., family physicians, diabetic services, and CKD clinic) is communication. 
The clinic should be viewed as a resource to both patients and parallel caregivers such as 
family and other physicians, and as such, could integrate care with other caregivers. For 
example, other caregivers could call to seek advice regarding safety of medications, and 
the clinic can serve as a facility to follow the patients during acute events (e.g. , increased 
creatinine around diarrhea and temporarily holding the ACE inhibitor). It is vital for such 
a clinic to communicate information about patient status, medications, plans, and so forth, 
not only to the patient but to all other caregivers involved (family physicians, diabetes 
clinic). 
When patients are accessing different care systems due to the complex nature of their 
disease or due to practical issues such as locale, it is not so clear how to determine the 
responsibility of each of the individual medical practitioners. Should the CKD clinic 
assume the ACE inhibitor is being managed by the heart failure clinic? Or does the CKD 
clinic asswne the diabetes clinic is managing the blood sugar control or counseling about 
smoking cessation? At what point in the stage of CKD does the CKD clinic take a more 
active role? These are not questions that will be answered in clinical trials, so practical 
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solutions to the issue of responsibility for care implementation will need to be developed. 
The key issue is the communication between different physician groups and medical 
teams and customization to individual patient and health care system particulars. There is 
an accumulating body of literature that suggests involvement of the patient in all 
implementation plans, and knowledge of and active involvement in therapy targets and 
test results improve the ability of physicians to implement care strategies [58-60]. 
Other Benefits of the CKD Clinic and Organized Protocolized Care 
The key to the care of patients with chronic disease is acknowledgement of the 
complexity of the conditions(s) and the need for longitudinal fo llow-up by a well-trained 
team. As in oncology, rheumatology, and other areas of medicine, the care of CKD 
patients requires some adoption of protocols for investigations, therapy, and follow-up 
(figure 1.3 and Table 1.3). In so doing, we will be able to develop sensible strategies 
bases on data, and management of selected conditions will be uniformly undertaken. The 
systematic evaluation and management of patients with chronic diseases has been 
demonstrated to reduce resource utilization and to enhance patient compliance. 
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Minimum follow-up I bloodwork intervals 
as a function of kidney function 
Creatinine Interval between visits I bloodwork 
Clearance 
(mUmin) Diabetics Non-diabetics 
31 -60 3 months 3 months 
15-30 2 months 3 months 
10-14 1 month 2 months 
<10 1 month 1 month 
Table 1.3 Example of a Protocol for Follow-up I Blood Work Intervals. Maximum 
intervals (or minimum frequency) between visits are given for stable patients. Shorter 
intervals may be necessary at discretion of physician or specialized nurse in less stable 
patients or be specified in therapy titration algorithms (e.g. initiation of erythropoietin 
replacement therapy). 
The additional advantages to the clinic models for the care of CKD include the ability to 
optimize all aspects of care by using individual team member' s expertise more 
appropriately and to optimize follow-up and monitoring of large groups of patients in one 
area. Furthermore, a clinic-based approach would allow database development and 
evaluation of outcomes in large cohorts of patients, the ability to enroll patients in clinical 
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trials, and importantly, the adoption of newer proven therapies may be easier in a clinic 
setting than in individual physician offices. 
Replete Iron stores 
Repeat ret ic count, 
And Hb in 1 month 
Anemia Management 
Figure 1.3 An example of a protocol for anemia management that may guide therapy by 
physician or specialized nurse. It assumes all secondary causes of anemia have been 
ruled out. ERT, erythropoietin replacement therapy; Hb, hemoglobin; mo, months 
The clinic structure may also ensure that patients have access to appropriate current 
information and materials that may not be available in individual physician offices. Also, 
it will permit coordinator of care plans and execution of those plans within any health 
system structure. 
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Barriers to care or implementation of strategies can be identified in a clinic setting. The 
costs and the nwnber of medications required for CKD is becoming progressively 
daunting and leads to problems with compliance. Furthermore, the potential ability to 
emphasize the role of patient and family in self management may be crucial where the 
interventions require lifestyle modification and I or adherence to complex medical 
therapies. These problems are more likely to be identified within a clinic setting, where 
social workers, pharmacists, and other may identify issues not identified by physicians. 
The importance of an asymptomatic condition can be reinforced in clinic setting where 
the patient-team interaction is far longer than the usual patient-doctor interaction [51]. 
Although there may be multiple problems and barriers that interfere with achieving the 
care goals in any one individual, the presence of an organized team approach is more 
likely to ensure the identification of those barriers in a timely manner. 
1.6 Other Studies 
The CAN-CARE (Canadian Care Prior to Dialysis) Study is a prospective multicenter 
cohort study of incident patients with estimated GFR less than 50 mL/min referred to 
nephrologists across Canada. Enrollment began November 2000 with a planned fo llow-
up of up to 4 years. The objectives are to describe: (1) the specific care ("elements") 
these patients receive over time, (2) the prevalence of cardio-renal risk factors at referral 
and at 12 and 24 months, and (3) the link between specific elements of care and outcomes 
I quality of life [11]. The Study ofTreatment for Renal Insufficiency: Data and 
Evaluation (STRIDE) registry will study data on prevalent CKD patients in nephrology 
practices in the United States [141]. The Chronic Renal Insufficiency Cohort (CRIC) 
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Study will examine risk factors for progression of CKD and CVD among those patients. 
The main goal is to develop models identifying high-risk subgroups and subsequently, 
increase application of preventive therapies [ 142]. The Kidney Early Evaluation Program 
(KEEP) was implemented to increase awareness to increase awareness of kidney disease 
among those at highest risk and, subsequently, to improve outcomes through early 
detection and referral for care. The KEEP 2.0 screening program identified persons with 
reduced kidney function and suboptimal care. The KEEP 3.0 will continue to identify 
individuals at high risk for kidney disease and will address educational needs by 
randomly assigning participants to one of several educational progran1s [ 143]. 
The Can-Prevent trial is a Canada-wide multicenter clinical trial addressing the 
hypothesis that compared to usual care, a nurse supported by a nephrologist, running a 
protocol guided, multiple risk factor intervention and disease management clinic for 
people with moderate chronic kidney disease identified by laboratory based case-finding, 
will reduce or delay the onset of advanced kidney disease, cardiovascular events, and 
death. The study will also assess the effect on health care resource use, costs and quality 
of life. Interventions applied will include lowering blood pressure to target, maximal use 
of renin-angiotensin system interruption, treatment of dyslipidemia, prophylactic aspirin 
when indicated, treatment of renal anemia, disordered calcium I phosphate and 
parathyroid metabolism, use of ~-blockers in heart failure and post myocardial infarction, 
control of diabetes, and smoking cessation. This trial is currently at an advanced stage of 
a pilot study that includes 500 cases randomized at five sites, with an average 2 year 
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follow-up scheduled to be complete by May 2008. No data have been published from 
this trial to date. 
1. 7 Conclusion 
Kidney disease involves the complex physical, mental, and social aspects of health 
mandating an understanding and rational utilization of available resources. Opportunities 
exist to improve early identification and follow-up of patients with CKD and to ensure 
better outcomes overall, regardless of whether patients ultimately require dialysis. 
In order to focus on these complex aspects of care, the inclusion of medical, nursing, 
dietary, social work, and pharmacy staff in a coordinated system, with protocolized goals 
and systematic approaches to longitudinal follow-up is required. It is hoped that the 
information supplied herein will help develop templates and delivery of care models for 
further evaluation, so that, ultimately, the outcomes of patients with CKD at all stages of 
disease are improved. 
46 
Chapter 2: Canadian Survey of Clinical Status at Dialysis Initiation 1998-99: 
A Multicentre Prospective Survey. 
Previously published as: Curtis B, Barrett BJ, Jindal K, Djurdjev 0 , Levin A for the 
Canadian Renal Disease Alliance: Clinical Nephrology 58(4):282-8, 2002. 
2.1 Introduction 
An understanding of current nephrological practice is essential for both the measurement 
of future success and the planning of care for patients with kidney disease. A number of 
recent publications recommend both earlier patient referral to a nephrologist [131-133, 
140, 144] and an earlier initiation of dialysis [ 111 , 135] with the intent that these 
interventions will lead to improved long-term outcomes of patients receiving kidney 
replacement therapy [145-147]. It is hoped, and indeed cohort studies suggest, that the 
specific intervention of care by a nephrologist improves quality of life and life 
expectancy. 
The timing of initiation of kidney replacement therapy should reflect a patient's estimated 
residual kidney function and/or symptoms. Key-measured elements at initiation, such as 
serum albumin and hemoglobin, have been shown to affect subsequent patient outcomes 
[42, 110, 112, 147-149]. Similarly, lack of preparation for dialysis increases morbidity 
and cost [ 131-13 3]. 
This cross-sectional survey of a convenience sample of dialysis units across Canada 
describes the status of patients commencing dialysis before the impact of recent 
guidelines. In describing current practice, we will be able to more rigorously define 
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objectives for future studies, and this information will serve as a baseline for initiatives in 
changing current care and attitudes. 
2.2 Patients and methods 
This Canadian multicentre cross-sectional study examined patients starting dialysis 
between October 1998 and December 1999. A letter was sent to Canadian community 
and university affiliated nephrology programs involved in existing collaborations 
requesting participation in the study. All centres that desired to participate in the study 
were included. Specifically, the centers were St. John's, Halifax, Montreal (2 centres), 
Quebec City, Toronto (2), Hamilton, Kingston, Winnipeg (2), Saskatoon, Vancouver (2) 
and Penticton. Centers ranged in size from 40 to over 500 prevalent patients and were 
predominately located in urban environments and affiliated with university-based 
teaching hospitals. These 15 centers represent almost two-thirds of current dialyzing 
centers in Canada. Each center selected a 1-month patient entry period according to their 
convenience. Within that 1-month period, consecutive patients starting dialysis in that 
center were entered. Patients with acute renal failure and with failing kidney transplants 
were excluded. Acute renal failure was defined as a new onset of potentially reversible 
cause of kidney failure requiring dialysis. Patients with acute "chronic kidney failure" 
were included in the data collection study. No attempts were made to modify any aspect 
of practice or therapy. 
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Data collection and measurements 
Data were collected on incident dialysis date and concurrent demographic variables (age, 
gender, diabetes), clinical variables (pre-dialysis weight, presence of symptoms), and 
laboratory measurements (pre-dialysis serum creatinine, albumin, hemoglobin, 24-hour 
urine urea and creatinine clearance). Standard laboratory measurements were used, 
specific to each institution. Specifically, albumin was measured using either the 
bromcresol green assay or bromcresol purple method. Results of bromcresol purple were 
adjusted for comparison purposes as per Clase et al [150]. Clinical symptoms were 
obtained using a checklist as close to dialysis initiation as possible and in some cases, 
collected retrospectively within a few weeks of starting dialysis. Each of the following 
was noted to be present or absent from the patient's perspective: nausea, vomiting, 
anorexia, cramps, itching, restless legs, fatigue and cognitive impairment. Severity of 
these symptoms was not quantified for simplicity of data collection purposes. 
Residual kidney function was calculated as creatinine clearance, estimated using the 
Cockcroft-Gault formula [151] and as glomerular filtration rate, using the "four-variable" 
(abbreviated) Modification of Diet in Renal Disease (MDRD) study equation (figure 2.1) 
[152]. Dialysis-specific information (modality, access) was recorded, as was whether a 
nephrologist had followed the patient for more than 3 months. Permanent access was 
defined as the presence of an A V fistula or graft, irrespective of maturity, a peritoneal 
dialysis (PD) catheter or a tunneled catheter that was planned to be used as long-term 
access. 
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Figure 2.1: Abbreviated MDRD Study Equation estimating glomerular filtration rate 
Estimated Glomerular Filtration Rate (ml/min/1.73 m2) 
= 186 x (Scr I 88.4)- 1.1s4 x (Age) -o.203 x 0.742 (if female) x 1.212 (if African-American) 
Abbreviations and units: Scr , Serum creatinine in J...tmol/L; Age, in years; Weight, in kg 
The following variables were analyzed at dialysis initiation: residual kidney function, 
presence or absence of permanent access, hemoglobin, serum albumin and presence or 
absence of symptoms. 
Data management and statistical analysis 
All data were collected at each site by nephrologists or in-training nephrology fellows 
and forwarded directly to a central data entry location (St. Paul's Hospital, Vancouver, 
Canada). Descriptive analyses are presented as mean ± standard deviation or median 
with 25th and 75th percentiles, when appropriate. Continuous variables were compared 
using the Student' s t-test or Wilcoxon rank sum test for comparisons between 2 groups 
and the ANOVA and Kruskal-Wallis test for comparisons of more than 2 groups 
depending on the distribution. Categorical variables were compared using the x} test. A 
p value of less than 0.05 for 2-sided tests is considered significant. 
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2.3 Results 
Demographics, laboratory data and dialysis access 
Data on 251 patients with end-stage kidney disease were collected; of these, 238 had 
sufficient data to be included in the analysis. At dialysis initiation, the mean estimated 
creatinine clearance was 10.9 ml/min using the Cockcroft-Gault formula, mean serum 
albumin was 32.7 g/L and mean hemoglobin was 92.6g/L. Only 41 patients had 
estimates of glomerular filtration rate measured by 24-hour urine collections for 
creatinine (and 9 patients for urea). In those 41 patients, the measured creatinine 
clearance was 8.6 mL/min; correlation between 24-hour measured and calculated using 
Cockcroft-Gault formula creatinine clearance was moderate (r = 0.45) and similar to 
those between 24-hour measured and MDRD formula (r = 0.51 ). The correlation of 
MDRD with serum creatinine is higher than that ofCockcroft-Gault formula (-0.91 vs.-
0.51), and the MDRD formula on average yielded a 2-3 mL/min lower estimate of 
residual kidney function than the Cockcroft-Gault formula (mean difference 2.9, range -
5.3 to 19.5). 
67% of patients commenced hemodialysis (vs. peritoneal dialysis) and ofthese 40% had 
permanent access. All patients starting peritoneal dialysis had permanent access in place 
at the time of this initiation, though not all patients with PD catheters commenced PD as 
their initial dialysis. 
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Exposure to nephrology care 
As demonstrated in Table 2.1, two thirds of patients ( 65%) in the sample were known to a 
nephrologist for more than 3 months prior to commencing dialysis. There was a 
significant difference in age (58 years vs. 63 years, p = 0.028) and in albumin levels (33.7 
g/L vs. 30.6 g/L, p = 0.0004) in those seen by nephrologists for more, versus less, than 3 
months. While there was no statistical difference in hemoglobin and residual kidney 
function between these groups, there was a trend toward lower values in those not seen 
by nephrologists. 
A greater percentage of patients had permanent access if a nephrologist had followed 
them for 3 months or more (p = 0.001). However, even ifpermanent access had been in 
place, 14 patients commenced dialysis through a temporary line. 
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Table 2.1 Summary Demographics and Status at dialysis initiation in those patients known 
and not known to a neQhrologist for greater than 3 months 
I 
CORR Datat All patients ' pt ' Known Not Known ' 
(1999) (n=238) 
' 
(n= 154) (n=84) 
' 
' 
Age (years) 61 59± 17 ' 58 ± 17 63 ± 16 0.028 
' 
' 
' 
' 
' 
Female(%) 41 43.7 43.5 44.1 0.94 
Diabetes Mellitus (%) 31.3 38.1 39.2 36.1 0.64 
Serum Creatinine 656 634 697 0.18 
(1-lmol/L) (521 -804) (532-785) (496-896) 
CrCl (ml/min) 10.9 ± 4.9 11.3 ±4.9 10.1 ± 4.7 0.057 
MDRD (ml/min) 8.0 ± 3.4 8.1 ±3. 1 7.7 ± 3.9 0.40 
Symptoms 3 (2-5) 3 (2-5) 3.5 (2-5) 0.33 
AI bum in (giL) 32.7 ± 6.3 33.7 ± 6.2 30.6 ± 6.0 0.0004 
Hemoglobin (g/L) 92.6 ± 18.1 94.3 ± 17.6 89.5 ± 18.6 0.051 
Initial Modality 78 66.7 67.5 65.1 0.70 
(o/o*HD) 
Permanent Access 79** 52.5 65.6 28.6 0.001 
(%) 
Temporary Line(%) 20** 53.2 41.2 75.0 0.001 
t See text for details, :j: denotes comparison of Known vs. Not Known, 
*HD - Hemodialysis, * * Represents prevalent data 
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Clinical Symptoms 
Frequency of symptoms reported by these patients is given in Figure 2.2. The most 
common symptoms were fatigue, anorexia and nausea, reported by more than 50% of 
subjects. The number of symptoms reported at dialysis initiation are reported in Table 
2.2: nearly 90% of patients had at least l symptom. Those with the lowest calculated 
MDRD glomerular filtration rate had the least number of symptoms. Low albumin was 
associated with the greatest number of symptoms. None of the other laboratory values 
correlated with symptom type or number. 
Symptoms at Dialysis Initiation 
Fatigue 0 0 0 -~ ' _ , , 0 o • 0 ;0~ ',-,_ ). '", , 0 ,.-.,_ 0 • ' I 
Anorexia 0 • 000-~ .~' '~ o • :-.'··{~ ';'0': ./ ~' ;'-c ' ~-:;' I 
Cramps ·, '/ ~ ~ ; ~- '•. I 
Restless Legs "'' ' 0 ~ , / I 
Cognitive Impairment '; -~ .-~~~~~~~ J 
0 20 40 60 80 100 
% of Patients Experiencing the Symptoms 
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Total(%) 
Age (years) 
Female(%) 
Diabetes Mellitus(%) 
CrCl (mL/min) 
MDRD (mL/min) 
Hemoglobin (g/L) 
Albumin (giL) 
Age and Diabetes 
Table 2.2 Symptoms at dialysis start 
No symptoms 
11.5 
56±21 
40.7 
26.9 
I 0.7±4.4 
8.0±3.1 
97.8±18.3 
35.2±6.5 
1 - 2 
symptoms 
27.8 
57± 17 
41.5 
31.3 
I 0.2±4.0 
6.9±2.6 
89.4±16.5 
33.7±5.1 
3 - 4 
symptoms 
29.5 
60±17 
46.4 
46.4 
11.1±5.6 
8.5±3.7 
94.9± 18.6 
32.8±6.7 
5 - 8 
symptoms 
31.2 
p 
62±15 0.26 
45.2 0.58 
42.5 0.07 
11.4±5.3 0.54 
8.4±3.8 0.03 
92.0± 18.9 0.16 
30.9±6.2 0.0084 
Table 2.3 shows the data divided according to 4 age cohorts. Older patients started 
dialysis with lower estimated creatinine clearance than younger patients. However, if the 
MDRD formula is used, the kidney function estimates are similar. Despite lower 
creatinine clearances, hemoglobin values were higher in the older age groups. A 
comparison of diabetics and non-diabetics is shown in Table 2.4. Diabetics started 
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dialysis with a higher calculated creatinine clearance and are more likely to do so with a 
temporary access. 
Table 2.3 Age group differences in status at dialysis start 
19-44 45-64 65-74 75 + p 
Total(%) 22.4 31.5 26.5 20.6 
Female(%) 45.1 50.1 33.3 44.9 0.23 
Diabetes Mellitus(%) 30.0 48.0 39.7 29.2 0.102 
Serum Creatinine 
(~-tmol/L) 
710 (581-914) 658 (517-840) 666 (510-798) 623 (486-685) 0.012 
CrCl (mL/min) 12.9±5.8 11.9 ± 5.0 10.0±3.7 8.5 ± 3.5 0.0001 
MDRD (mL/min) 7.7 ± 3.5 7.8 ± 3.4 7.9 ± 3.3 8.5 ± 3.5 0.58 
Hemoglobin (g/L) 89.3 ± 25.3 89.6 ± 14.7 95.0 ± 17.0 97.4 ± 13.8 0.042 
Albumin (g/L) 33.3 ± 7.2 32.2 ± 6.2 32.3 ± 5.7 33.0 ± 6.4 0.79 
Modality(% HD) 50.9 73.3 63.1 73.5 0.043 
Permanent Access (%) 64.7 48.0 54.0 44.9 0.18 
Temporary Line(%) 39.2 61.3 50.8 58.3 0.084 
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Table 2.4 Comparison of diabetics and non-diabetics patients 
Diabetics Non-diabetics p 
Age (years) 60 ± 15 59 ± 18 0.89 
Female(%) 48.9 40.4 0.20 
Serum Creatinine (~J.mol/L) 631 (502-773) 666 (540-843) 0.062 
CrCI (mL/min) 12.2±5.8 10.1 ± 4.0 0.0011 
MDRD (mL/min) 8.4 ± 3.7 7.7 ± 3.2 0.18 
Hemoglobin (g/L) 91.9 ± 18.3 93.0 ± 17.9 0.68 
Albumin (g/L) 31.7 ± 6.0 33.2 ± 6.5 0.097 
Modality(% HD) 70.0 64.8 0.41 
Permanent Access (%) 45.6 56.2 0.11 
Temporary Line(%) 64.0 47.3 0.012 
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2.4 Discussion 
We have described the characteristics of end-stage kidney disease patients initiating 
dialysis across Canada. Previous studies have addressed similar issues but have involved 
only single centers or multiple centers involving multiple health care systems [42, 145, 
153, 154]. Our study is unique in that it surveyed multiple centers within a single health 
care system across 7 provinces. Furthermore, this study was conducted in the current era 
during which both the Dialysis Outcomes and Quality Initiative and Canadian Society of 
Nephrology guidelines concerning dialysis initiation were being developed and 
published. This provides us with baseline data from which to evaluate the impact of 
guideline implementation in the future. 
We, like others, identify that substantial numbers of patients are not seen by 
nephrologists before the initiation of dialysis. Similar to other studies, lack of 
nephrology care is associated with lower serum albumin, hemoglobin and lack of 
vascular access. These factors have been shown in numerous publications to be 
associated with an increase in morbidity and mortality [42, 110, 112, 131-133, 147-149]. 
The cost and morbidity implications of temporary catheter access are extensive. They 
include the cost of catheters themselves, insertion fees, radiology tests and costs 
associated with complications such as infection and thrombosis. 
Of note, however, patients known to nephrologists also start with temporary access to a 
significant degree (41%). While this is almost half the rate as compared to those who 
were not known (75%), it is still of concern. It may be that the conventional cut-off of 3 
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months, used in previous studies, and based on the premise that this allows time to 
establish permanent access is inappropriate. Current guidelines for access creation 
suggest that GFR<25mL/min or 6 months in advance of dialysis initiation is needed for 
adequate vascular access maturation and the insertion of PD catheters between 2 and 3 
weeks prior to use (depending on techniques used). Thus, the fact that even those known 
to nephrologists did not all commence dialysis with permanent access may be a function 
of poorly defined cut-offs for late referral. Unfortunately, we did not collect specific 
information of data of first contact with a nephrologist, and thus, are unable to review 
other possible time point cut-offs. This study was unable to capture reasons for "late" 
referral, but does serve to document that late referral continues to exist in the Canadian 
health care system. 
The utility of various formulas for estimating kidney function was not a major focus of 
this study. However, we did observe the "performance" of the MDRD formula relative to 
the Cockcroft-Gault formula and the 24-hour urine collection. This provided interesting 
results. While the estimated creatinine clearance showed no relation to the number of 
symptoms, the MDRD formula showed a lower symptom frequency with lower 
glomerular filtration rate, suggesting that patients with less severe symptoms started 
dialysis later. Conversely, while values for creatinine clearance varied in different age 
cohorts and diabetics vs. non-diabetics, the MDRD values were similar, suggesting 
significant differences in the performance of these formulas in these populations. It is 
well-known that at lower levels of kidney function, the Cockcroft-Gault formula 
overestimates glomerular filtration rate: this is borne out by the data in this study, if 
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MDRD and 24-hour values are viewed as relative "gold standards". Recent 
recommendations suggest the use of any formula versus serum creatinine alone improves 
estimates of kidney function [3 6]. 
This study is the first dialysis initiation study to review symptoms in relation to the 
timing of dialysis start in Canada. We note that the majority of patients commence 
dialysis with at least 3 symptoms, and those are most commonly, fatigue, anorexia and 
nausea. Those with low albumin had a greater number of symptoms and yet a higher 
MDRD glomerular filtration rate suggesting the non-specific nature of the symptoms and 
possible correlation with factors other than residual kidney function . 
The strength of this study is that it surveys current practice during a time of increasing 
attention to the quality of dialysis care, including initiation practices. Although the 
centers included were largely academic, 80% of current dialyzing centers in Canada are 
affiliated with university-bases teaching hospitals. Limited available data on both 
incident and prevalent patients from the Canadian Organ Replacement Registry (CORR) 
demonstrate similarity with respect to demographics as shown in Table 2.1 [155). No 
other incident data exist for comparison between this cohort and the Canadian dialysis 
population. It is the first study in Canada which attempts to determine presence of 
symptoms at dialysis initiation, as well as laboratory and clinical values. Weaknesses 
include: lack of clear documentation as to decision processes prior to dialysis initiation 
(both patient and physician), lack of documentation as to reasons for late referral and the 
arbitrary selection of 3 months of nephrology exposure as being an "acceptable" time 
60 
prior to dialysis initiation to ensure improved outcomes. The latter is based on current 
convention in the literature, but will need to be revisited in future studies if patients 
continue to initiate dialysis as described in this survey. Furthermore, the uremic 
symptoms we were interested in were limited to those easily captured and did not include 
other comorbid features such as cardiovascular disease or sexual dysfunction. These 
additional factors would be included in future studies. 
This survey of dialysis initiation practices in Canada during 1998-1999, demonstrates that 
Canadian patients are commencing dialysis in a similar condition to that of patients in 
other western countries [132, 145, 153, 154]. Unfortunately, the presence oflow 
hemoglobin, hypoalbuminemia, symptoms and lack of permanent access continue to be 
prevalent, irrespective of whether patients have or have not been seen by nephrologists 
prior to dialysis initiation. Although this survey was not designed to properly evaluate 
the question of sub-optimal nephrological care there is certainly an apparent "advantage" 
to nephrology referral at least 3 months prior to initiation of dialysis. This is true with 
respect to status at initiation (trend toward higher hemoglobin, higher albumin and the 
presence of an access) relative to not being known to a nephrologist for at least 3 months, 
but from the data presented there is variability in patient conditions at dialysis start 
irrespective. 
Of key interest is that of patients referred late to nephrologists, a substantial proportion 
belongs to an identifiable high-risk group (diabetics). Given the exposure of these 
patients to a medical system, it is clear that we need to continue rigorous public and 
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medical education strategies to identify reasons for late referrals. In this way, we may 
substantially reduce the prevalence of late referrals and improve patient outcomes [ 40]. 
The importance of this study is that it serves as a baseline from which to evaluate the 
impact of focused educational strategies, early referral and improved management of 
patients prior to dialysis care. If we are to improve timeliness of referral and patient 
outcomes it is important to identify those barriers that continue to interfere with 
optimizing the management of patients with kidney disease. 
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Chapter 3: The Short and Long Term Impact of Multi-Disciplinary Clinics in 
Addition to Standard Nephrology Care on Patient Outcomes. 
Previously published as: Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, 
Djurdjev 0 , Levin A, Nephrol Dial Trans 2005 Jan;20(1): 147-54. 
3.1 Introduction 
Mortality and morbidity of kidney failure patients remains high despite the many 
advances in dialysis treatment [ 1, 155-157]. Indeed, kidney failure is a culmination of a 
complex set of processes with widespread pathophysiological consequences. It is well 
recognized that much of the disease burden is well established prior to the initiation of 
dialysis therapy [43, 158]. Opportunity thus exists for proactive intervention to modify 
disease progression and risk factors associated with poor outcomes. 
Although it is believed that a nephrology team is important in the management of patients 
with kidney disease [51 , 53, 140, 156, 159], there is no uniform definition of such a team, 
nor a description of implementation practices. Given that multi-disciplinary teams 
impact on health care resources, it is imperative to evaluate their effectiveness in 
comparison to current clinical practice. The impact of a multi-disciplinary team clinic 
has been studied in other disciplines such as diabetology [12, 13, 45] , cardiology [14-16, 
18, 46], rheumatology [47, 48] , and oncology [50] and shown to benefit patient care and 
outcomes. 
There is substantial evidence that late referral leads to poor outcomes for patients with 
kidney disease and that early referral is of benefit [131-133, 144]. The unique purpose of 
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this study was to examine patient outcomes as a function of two different clinical care 
model exposures, both over a prolonged period of pre-dialysis time: that is, we sought to 
examine the question of the effect of different care when late referral is not an issue. We 
compare two cohorts of patients who commenced dialysis in two countries. All patients 
had been exposed to conventional nephrologist care or nephrologist and multi-
disciplinary team care for an extended period of time. We evaluated the impact of care 
prior to dialysis on survival and other objective parameters shown to influence long-term 
outcomes [42, 148]. This study extends previous observations [51] into the current era, 
and internationally, in order to improve the generalizability of the findings. 
3.2 Patients and Methods 
This study of incident dialysis patients examines those patients initiating dialysis in two 
tertiary care institutions: St. Paul's Hospital (SPH), University of British Columbia, 
Vancouver, Canada and Instituti Ospitalieri di Cremona, Italy. In the Canadian cohort, 
patients commencing chronic dialysis at SPH during calendar years 1997 and 1998 were 
considered for inclusion. In the Italian cohort, all patients commencing dialysis in 
Cremona from 1 January 1999 until 30 June 2002 were considered. The total cohort of 
dialysis patients during the time periods was 352, but only adult patients (over the age of 
18 years) and those followed by nephrologists for more than 3 months were eligible for 
inclusion for this analysis, given the specific questions being addressed. The 3 month 
convention attempts to remove patients with ' late referral ' based on duration oftime 
needed for education, modality selection and access creation in a non-urgent manner. All 
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patients gave informed consent and local ethics boards of each respective institution 
approved the study. 
Patients were categorized according to prior exposure to a multi-disciplinary clinic-based 
education and follow-up program and compared with a concurrent cohort who received 
standard nephrologist care in the same centres. Details of the MDC are described below. 
Patients were excluded if they had a failed kidney transplant or had been on dialysis 
previously for any reason. 
In both countries, the dialysis centres are accessed by patients who are from the same 
referral group practice and referral base of nephrologists. All nephrologists in each 
centre had the same opportunity to access facilities and personnel of the multi-
disciplinary clinic for their patients. The reasons for non-referral or non-attendance at the 
clinic were not obtained. Care after dialysis initiation was standardized and managed 
according to unit practices. 
Details of the multi-disciplinary clinic have been described in more detail elsewhere [51]. 
Briefly, the formal programs in both Canada and Italy have a standardized philosophy 
including educational programs as well as regular, protocolized clinic and laboratory 
follow-up of patients with chronic kidney disease. The frequency of both visits and 
laboratory tests is predetermined based on the level of kidney function with reminder 
systems to facilitate follow-up. Regularly scheduled blood work and clinical 
examinations and pre-specified educational topics are reviewed with each patient. 
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In the Canadian centre, the complete formalized multi-disciplinary clinic team consists of 
a nurse educator, physician, social worker, nutritionist, and pharmacist, though exposure 
to each individual is varied depending on level of glomerular filtration rate (GFR). In the 
Italian centre the team consists of program-dedicated nephrologists and multi-disciplinary 
nurses responsible for implementation of recommended diagnostic and intervention 
strategies, information, education and support. The formal team accesses the nutritionist, 
psychologist, and social worker when necessary. 
In both countries the average duration of exposure of the patient to the team is 
approximately 1.5 hour per visit (range 1-2.5 h). The average number of visits per 
patient-year depends on the protocol, determined by level of kidney function. For the 
purposes of this analysis, it is estimated at five visits per year (including a specialized 
education visit for treatment modality selection at 2 h), thus total exposure to the clinic 
team is approximately 8 h ( 4 x 1.5 + 2 h) per patient-year. The average duration of visits 
to the nephrology office is estimated to be 0.5 h based on office booking schedules. For 
the purposes of comparison, the number of visits to nephrologist offices is estimated to be 
the same number: 5 ( 4 x 0.5 +the same 2 h specialized education session). Thus, patients 
attending nephrology offices had 'exposure' for- 4 h per patient-year. Note that the 
timing of the 2 h educational session was left to the discretion of the nephrologist for the 
standard nephrology care patients; however, the same staff from the multi-disciplinary 
clinic performed it. Thus all patients were exposed to the identical information session. 
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In Italy, patients in the formal program participate in three 2 h educational dialysis 
orientation meetings over 3 months, culminating in additional 6 h of education exposure. 
Those patients who do not attend the program received orientation to dialysis by the 
physician in charge and the program team; the timing of this is again at the discretion of 
the nephrologist, and occurs closer to dialysis start than those attending the formal 
program. 
Date collection and measurements 
Data were collected on all patients at the time of dialysis initiation, by research 
assistants. Baseline data included demographic, diabetic status, etiology of kidney 
failure, date of first nephrology referral and dialysis modality. Serial laboratory data 
were collected on all patients at the time of dialysis initiation and at follow-up intervals 
of 6 and 12 months. Patient status (on dialysis, deceased, transplanted, discontinued 
treatment, or moved) was also obtained at the end of the study period for each cohort. 
Statistical analysis 
Descriptive analyses are presented as mean ± standard deviation. Continuous variables 
were compared using the Student's t-test or Wilcoxon rank-sum test depending on 
distribution. Categorical variables were compared using the chi-squared test. Multiple 
linear regression was used to investigate independent predictors of short-term outcomes 
(differences in laboratory data at dialysis initiation) adjusting for age, sex, race, diabetes, 
etiology of kidney failure, estimated kidney function at dialysis initiation, country and 
attendance of multi-disciplinary clinic (MDC). Survival on dialysis was examined using 
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the Kaplan-Meier method and survival by clinic attendance was compared using the log-
rank test. Patients were censored at transplant, moving away, and end of study period. 
Cox proportional hazards modeling was used to examine hazard ratios for death as 
outcome. Multivariate modeling explored the impact of MDC on survival adjusting for 
variables found previously to impact on survival: age, gender, race, diabetes, duration of 
follow-up prior to dialysis and country. A p-value of < 0.05 for two-sided tests was 
considered significant. 
3.3 Results 
The total eligible cohort of288 patients consisted of 152 patients in the Canadian cohort 
and 136 patients in the Italian cohort. During the time period of interest, 352 people 
started dialysis, of which 64 (18%) were referred to nephrologists <3 months prior to 
dialysis start. These study cohort populations are similar in demographics to those 
described in national registries from both Canada and Italy [9, 155, 160]. The only 
cohort difference between the two countries was racial distribution. All data were thus 
combined with country and race factored into analyses. 
Table 3.1 demonstrates the demographic and initial laboratory data at dialysis initiation 
for the 288 eligible patients: note that all patients had an average of 42 months of 
nephrology care prior to dialysis. Comparisons between those patients seen in the MDC 
(n = 132) vs. standard nephrology care (n = 156) are presented. Age and race are 
statistically significantly different between the two groups, with those exposed to the 
MDC being younger (64 vs. 60 years) and of different racial composition (more East 
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Indian and less Asians). Analysis of the age distributions confirms similar ranges in both 
groups. 
Patients in both groups commenced dialysis at mean levels of kidney function that were 
low (below 9 mL/min/1.73m2). The estimated GFR using the ' four variable ' 
(abbreviated) Modification of Diet in Renal Disease (MDRD) study equation [152], was 
statistically significantly different between the two groups: those attending the MDC 
started dialysis with mean GFR values of 8.4 mL/min/1. 73m2, vs. those receiving 
standard nephrology care alone, who had a mean GFR of7.0 mL/min/1.73m2 (a mean 
difference between the groups of 1.4, 95% CI: 0.6-2.2 mL/min/1.73m2) . In both cohorts, 
~60% commenced hemodialysis, and 40% commenced peritoneal dialysis therapy. 
Home-based hemodialysis therapy was not an option at the time of study. 
Short-term outcomes: differences in laboratory outcomes at dialysis initiation. 
Table 3.2 describes the laboratory data at dialysis initiation as a function of MDC 
exposure or standard nephrology care.· There were significant differences with respect to 
hemoglobin (102 vs. 90 g/L, p<O.OOOl), albumin (37.0 vs. 34.8 g/L, p=0.002) and 
calcium (2.29 vs. 2.16 mmol/L, p<O.OOOl) levels in those patients followed in the multi-
disciplinary clinic vs. those followed by nephrologist alone. The difference in 
hemoglobin levels persists during the first year, while the values for calcium and albumin 
become similar over the course of dialysis. Note that phosphate levels were not different. 
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Table 3.1. Demographics at Dialysis Initiation. All patients known to Nephrologist for > 3 Months 
Standard Nephrologist Entire Nephrologist and Multi-Cohort Disciplinary pt Office Care Clinic 
N (%) 288 156 132 
Clinic Duration (months) 41 ± 34 43 ± 34 40 ± 33 0.4 
Age (years) 62 ± 16 64 ± 16 60 ± 17 0.02 
Female(%) 39.9 43.6 35.6 0.2 
Diabetes (%) 33.7 33 .3 34.1 0.9 
Race(%) 
0.001 
Caucasian 72.1 66.4 78.9 
Asian 17.1 25.0 7.8 
East Indian 6.4 3.3 10.2 
Other 2.5 2.6 2.3 
Etiology of Kidney Failure(%) 0.5 
Diabetes 22.3 20.5 24.4 
Hypertension 20.2 21.2 19.1 
GN* I Autoimmune 24.7 23.1 26.7 
Cystic Disease 7.3 5.8 9.2 
Chronic Kidney Disease** 13.6 16.0 10.7 
Other 11.8 13.5 9.9 
Dialysis Modality§ (% HD) 60.4 61.5 59.1 0.7 
t denotes comparison between Nephrologist and Multi-Disciplinary Clinic vs. Standard 
Nephrologist Office Care; *GN - Glomerulonephritis; **Not otherwise specified; 
§Percentage of those starting Dialysis, HD - Hemodialysis (versus peritoneal dialysis) 
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Table 3.2 Laboratory data (mean ± standard deviation) at dialysis start, 6 and 12 months post 
dialysis 
Standard Nephrologist Nephrologist and 
Office Care Multi-disciplinary Clinic p 
Kidney Function at Dialysis start 
Creatinine ()lmol/L) 707 ± 188 650 ± 225 0.03 
GFRt (mL/min/m2) 7.0 ±2.6 8.4 ± 3.8 0.001 
Hemoglobin (g/L) 
Dialysis start 90 ± 14 102 ± 18 <0.0001 
6 months 108 ± 15 116± 16 <0.0001 
12 months 110± 17 120 ± 16 
<0.0001 
AI bum in (g/L) 
Dialysis start 34.8 ± 5.3 37.0 ± 5.4 0.002 
6 months 36.5 ± 4.5 37.0 ± 4.7 
0.4 
12 months 36.9 ± 4.6 37.0 ± 4.2 0.9 
Calcium (mmol/L) 
Dialysis start 2.16±0.27 2.29 ± 0.21 <0.0001 
6 months 2.33 ± 0.24 2.32 ± 0.22 0.9 
12 months 2.28 ± 0.21 2.29±0.17 
0.6 
Phosphate (mmol/L) 
Dialysis start 1.73 ± 0.55 1.73 ± 0.54 0.9 
6 months 1.56 ± 0.51 1.61 ± 0.43 0.4 
12 months 1.61 ± 0.47 1.59 ± 0.44 0.8 
tGFR estimated by abbreviated MDRD formula 
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In a multivariate model, MDC was independently associated with higher hemoglobin 
(~=12.5 ± 1.9, p<O.OOl), calcium(~ = 0.14 ± 0.03, p< 0.0001) and albumin (p = 2.2 ± 
0.7, p=0.002) at dialysis initiation after adjusting for age, sex, calculated GFR at dialysis 
start, race, diabetes, etiology of kidney failure, and country of treatment. 
Long term outcomes: survival analysis 
Patients were followed for a median of 14 months after dialysis start. There were 
differences in important clinical outcomes after dialysis initiation. In the standard 
nephrology group 12 patients had been transplanted, one had transferred and 46 had died; 
in those followed by the MDC, seven had been transplanted, two had transferred, and 13 
had died. Figure 3.1 demonstrates the difference in survival after dialysis initiation, 
between patients who attended the MDC vs. those who received standard care, using 
Kaplan-Meier analysis. Note the statistically significant survival advantage of those 
attending the MDC over those patients in the standard nephrology cohort (p = 0.01 ). 
Multivariate modeling revealed only age and MDC to be significant predictors of survival 
(Figure 3.2). Age per 5 years (hazards ratio = 1.36, 95% confidence interval 1.21- 1.54) 
and standard nephrology clinic vs. MDC attendance (hazards ratio = 2.17, 95% 
confidence interval 1.11-4.28) were statistically significant independent predictors of 
death. 
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Figure 3.1 Kaplan-Meier survival after starting chronic dialysis therapy. Comparison is 
made between patients seen prior to dialysis initiation in The Multidisciplinary Clinic 
(MDC) versus standard nephrology care 
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Figure 3.2 Risk of death according to multivariate Cox-Proportional hazards modeling. 
Comparator for race is Caucasian. 
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3.4 Discussion 
This two country observational study is the first to demonstrate an association between an 
exposure to formal MDC-based care and survival benefit of patients starting dialysis. 
Despite similar long exposure times to expert care, those patients exposed to the 
formalized clinic had higher levels of serum hemoglobin, albumin, and calcium at 
dialysis start than those followed by standard nephrology care. These measures may be 
viewed as markers of exposure to care (e.g. nutrition counseling) and have been shown in 
numerous publications to be associated with a decrease in morbidity and mortality [ 42, 
148]. In fact this analysis demonstrates that MDC care impacts on these parameters 
independent of GFR: that is, the findings of better laboratory parameters are not 
explained by higher GFR in that cohort receiving MDC care. 
The survival advantage of the multi-disciplinary clinic cohort persists despite adjusting in 
the Cox proportional hazards model for baseline variables known to impact survival: e.g. 
age, gender, race and diabetes. There were two major differences in the demographics of 
the cohorts: age and race. The statistically significant 4 year difference in age is of 
questionable clinical importance. Racial differences are less easy to interpret and may 
represent patient preference for care patterns, cultural attitudes or a combination of both. 
As this study seeks to describe the outcomes of exposure to a specific treatment, this 
finding does not change the conclusions, but does raise further questions for exploration. 
Of note Asian I Oriental race is usually associated with better outcomes and East Indian 
and Caucasian with worse outcomes. Thus, the racial distribution differences would 
serve to bias the analysis against the formalized clinic cohort. While there was a 
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statistical difference between the two groups with respect to GFR at dialysis start, the 
clinical importance of 1.4 mL/min/1. 73m2 at levels below 9 mL/min/1. 73m2 is not clear, 
but unlikely to account for all the findings. Importantly, we did not adjust for 
hemoglobin and albumin in the survival analysis, as these variables were themselves 
impacted directly by our treatment of interest: MDC exposure. Therefore, statistically 
we could not adjust for a phenomenon that occurred as a consequence of the treatment of 
interest, at a time point after the exposure. Thus, while it is well known that lower values 
of hemoglobin and albumin at dialysis start impact on long-term outcomes, our analysis 
demonstrates one mechanism by which these values may be modifiable in a cohort 
known to nephrologists for a prolonged period of time. Furthermore, we did not adjust 
for factors which would have been in evidence after dialysis start (such as adequacy of 
dialysis, severity of illness measures) as our analysis was confined to those factors which 
would exist prior to dialysis initiation. While it is clear that survival is impacted by 
adequacy of dialysis and other factors , these factors would not be known to clinicians at 
the time of initiation, and thus would not be available to inform clinicians as to prognosis: 
this analysis clearly describes the importance of status at dialysis initiation. 
The data from the two countries are not concurrent; this is due to the late implementation 
of the formal program in Italy, which was modeled after the Vancouver program. 
Nonetheless, the similarity of the programs, as one was based on the other, despite the 
different time periods, allows us to combine the data. Importantly, the results 
demonstrate that even in a more current era, with increasing awareness of the importance 
of care prior to dialysis, differences in outcomes are maintained. 
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This study is not a randomized control trial (RCT), thus the nature of the cohort design 
does not allow us to rule out a referral or case mix bias affecting our results. However, it 
is important to stress that all patients had equal opportunities to be referred to the clinic, 
given that the group of university affiliated physicians belonged to the same practice 
group in the same geographical area, and used the same hospital and educational 
resources. While attitudinal differences between physicians may exist, the knowledge of 
the importance of hemoglobin, albumin and other parameters is probably identical. The 
analysis confirms similar time of follow-up and similar patient cohorts, apart from age 
and ethnicity. We are unable to know with certainty if there are other unmeasured 
variables impacting on these results such as blood pressure control or aspects of patients' 
attitudes. The possibility of selection bias of course remains a weakness of this study, 
and for this reason we advocate the need for a RCT in order to definitively answer the 
questions posed herein. 
There has been only one RCT in patients with kidney disease, published by Harris et al 
[54], which did not demonstrate a benefit to case management in chronic kidney disease. 
The intervention in that study was very different to our study as it was limited to written 
suggestions made to primary care physicians and the assigned clinic patients did not 
receive any specific treatment or preparation for kidney replacement therapy. This is in 
contrast to our study in which treatments were implemented directly by clinical staff. 
Thus, failure to show a benefit in the Harris study may well have been due to the failure 
of individual primary care physicians to implement the recommendations from the clinic. 
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There are numerous examples of benefit of the MDC in chronic illnesses, which do 
demonstrate benefit in patient outcomes [ 12, 13, 16, 18, 45-48, 50]. The current analysis 
specifically compares sophisticated clinic programs, which include protocolized 
objectives of care, specific treatment regimens and education to solitary nephrology care. 
Given the difficulties in conducting randomized control trials of care delivery systems, 
this study is of value. Indeed, a recent review by Po we [ 161] describes the need for 
carefully conducted studies such as this where exposure time, methods and outcomes are 
carefully tracked, as an alternative to the RCT. We believe the current analysis 
demonstrates the value of this approach, but does not obviate the need for randomized 
control trials, as mentioned above. 
The reasons for improved laboratory and clinical outcomes despite similar length of time 
exposed to nephrology expertise are not clear but are probably multi-factorial as the 
finding argues for the potential added value of a team managing the complex set of 
factors within individual patients with chronic kidney disease (CKD). We are not able to 
determine which individual aspects of the programs are responsible for the findings. It is 
likely that variables or combinations ofvariables, such as attitudes and compliance that 
are difficult to measure may contribute. As we do not have reliable data regarding initial 
GFR at time of initial referral in all patients, it is possible that slower progression of those 
exposed to MDC care may account for the findings. This would require additional 
confirmation with extended studies. Certainly the duration of individual patient exposure 
per interaction of at least 2 times longer (8 vs. 4 h), despite similar total patient exposure 
in months, could be important. We hypothesize that a number of qualitative, not just 
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quantitative, differences in exposure contributed to the outcomes. Importantly, the actual 
time spent with the patients may overtly reinforce the importance of the condition to the 
patients, thereby influencing patient compliance and thus outcomes. 
We chose to focus on only those persons who had been exposed to nephrologists for > 3 
months prior to dialysis start. This 3 month cut-off is a construct derived from the 
literature; importantly for this analysis, it serves to eliminate those patients truly referred 
late. Current guidelines suggest that up to 6 months in advance of dialysis initiation may 
be needed for adequate vascular access maturation and optimization of care [ 40, 162]. 
Nonetheless, even using this 3 month cut-off, the exposure to nephrologists in both 
groups of interest (formal clinic and nephrology alone) still averaged 42 months: well 
over 3 years of clinical care. This study then describes the outcomes of patients followed 
for substantial periods of time. The finding that patients chose hemodialysis 60% of the 
time irrespective of care model is interesting. It is noted that 60% is well below the 
national average in both countries (Canada 72%, Italy 89%; and in both regions - 70%) 
thus indicating the higher propensity for these patients to choose home-based peritoneal 
dialysis as their treatment of choice. This corroborates other studies of early vs. late 
referral which demonstrate that those referred early are more likely to choose 
independent-based care than those who are referred later [133]. 
There is increasing recognition of the importance of CKD [5, 86] and a growing number 
of CKD patients. It is imperative to develop evidence-based strategies that maximize 
outcomes. The importance of early referral to nephrologists is not disputed and has been 
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well described by many authors to date [131-133, 144]. Early referral is essential to 
identify the myriad of abnormalities, and plans for their treatment are best achieved in 
consultation with specialist care. However, it may be that the ability of individual 
nephrologists to attend to the multiple and complex aspects of care in this patient group, 
in the absence of formal clinic teams, is limited. Publications using United States [ 42, 
163] and Canadian data [ 164] demonstrate that even the care of patients with CKD who 
are known to nephrologists continues to be suboptimal. Out study corroborates these 
findings. 
In summary, this study suggests that even after appropriate and timely referral to a 
nephrologist, there is additional value of a multi-disciplinary team in optimizing both 
short, and long-term patient outcomes [5 , 12]. Uniquely, we extend observations of 
previous studies and demonstrate a potential survival advantage of formal MDCs. The 
value of each of the components of the clinic program (i.e. personnel, protocol driven 
laboratory I visit schedule and treatment plans) is not known. Research needs to be 
undertaken to prospectively follow patients from entry into the nephrology I MDC care to 
confirm these findings and determine whether other objectives of the clinic, such as 
delaying progression, are met. 
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Chapter 4: Evaluation and treatment of CKD patients before and at their first 
Nephrologist Encounter in Canada 
Previously published as: Curtis BM, Barrett BJ, Djurdjev 0, Singer J, Levin A. 
Evaluation and treatment of CKD patients before and at their first nephrologist encounter 
in Canada. Am J Kidney Dis. 2007 Nov; 50(5):733-42 
4.1 Introduction 
The burden of illness in dialysis patients remains unacceptably high [1, 165, 166]. Many 
of the co-morbid conditions impacting on long-term morbidity and mortality are present 
in earlier stages of chronic kidney disease (CKD) and are modifiable by education, 
nutritional counselling, and drug therapies [ 4, 167, 168]. The goals of care for patients 
with CKD thus include delay of progression of kidney disease and evaluation and 
treatment of comorbid conditions and complications. 
Although our understanding of the epidemiological characteristics of risk factors for 
adverse outcomes in dialysis patients has improved, we do not have a good understanding 
of those in patients with CKD not yet on dialysis therapy. Specific factors linked to 
adverse patient outcomes include anemia, hypertension, malnutrition, academia, and 
abnormal mineral and bone metabolism. Data from both the United States and Canada 
showed that even in patients followed up by nephrologists, many of these factors were 
evident at dialysis therapy initiation [9, 10, 169-171]. However, it is not known whether 
this was caused by a lack of optimal CKD care. 
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Although some studies described care models for chronic disease (12, 17], and 
multidisciplinary care in patients with CKD [8, 10, 168, 171-173], no formal definition or 
evaluation of the structure and elements of nephrology care was developed. In addition, it 
is not clear which elements of care are essential to achieve optimal outcomes. 
The main objectives of this study are to describe: 1) characteristics of patients at their 
first nephrology encounter in Canada; 2) evaluation for cardiac risk factors, cardiac 
diseases, and CKD complications and their management before the encounter; 3) changes 
in management initiated by nephrologists at the first encounter; and 4) the availability 
and use of allied health professional services for CKD care. This exploration will enable 
the identification of strategies to improve CKD care from both physician and system 
perspectives. 
4.2 Methods 
This study is part of the Canadian Care Prior to Dialysis (Can-Care) Study, a larger peer-
reviewed study partly funded by the Kidney Foundation of Canada in conjunction with 
both Baxter Canada and Ortho Biotech Canada. It is a Canadian prospective multi-centre 
observational cohort study designed to enroll consecutive patients with glomerular 
filtration rate (GFR) < 50 mL/min/1.73m2 (< 0.83 mL/s/1 .73 m2; measured or estimated 
by any means) at their first encounter with a nephrologist. The 4-variable (isotope 
dilution mass spectrometry) Modification of Diet in Renal Disease (MDRD) Study 
equation (152] was used to estimate GFR. This study was conducted before creatinine 
standardization or calibration in Canada. 
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Patients were enrolled between November 2000 and March 2004. At the time of study 
initiation, Canadian recommendations were to refer patients to a nephrologist if: 1) serum 
creatinine greater than 3.4 mg/dL (>300 )lmol/L), 2) creatinine clearance less than 30 
mL/min (< 0.50 mL/s), or 3) serum creatinine is increasing rapidly (40]. The Canadian 
health care system provides universal coverage, and specialist referral does not generate 
direct cost to patients or disincentives to the referring provider. However, documentation 
accompanying referral requests may vary from "please see this patient with possible 
abnormal kidney function" to very detailed letters with complete workup documented. 
Subsequent to referral, nephrologists decide to either discharge the patient back to care of 
the referring physician (usually with recommendations and suggestions for later referral 
if needed) or continue co-management with the referring physician 
The aim of the overall Can-Care study is to evaluate the hypothesis that exposure of 
patients with CKD to specific elements of care leads to the achievement of target values 
for factors linked to morbidity and mortality in dialysis patients. The objectives of the 
Can-Care study are as follows: 1) to describe the elements of care to which patients with 
CKD are exposed. The major elements include timing, frequency, extent and I or use of 
protocol for a) laboratory measurement, b) clinical evaluation (weight, blood pressure, 
and medication review), c) nutritional counseling, d) educational programs, and e) 
interaction with a multidisciplinary team; 2) to describe the prevalence of laboratory 
abnormalities and hypertension at the time of referral and yearly (up to 4 years); 3) to 
explore the link between elements of care and outcomes (including quality of life). 
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The participating centres included both community-based practices (Kamloops, BC; 
Penticton, BC) and urban university settings (Vancouver, BC; Saskatoon, SK; Winnipeg, 
MB [2 sites); Toronto, ON [2 sites]; London, ON; Montreal, QC; Quebec City, QC; 
Halifax, NS; St. John's, NL). Patients with acute kidney failure were excluded, as were 
patients with CKD believed likely to require dialysis therapy within 3 months of referral 
(e.g. "acutely recognized" CKD). No attempt to direct practice, alter therapy, or modify 
follow-up patterns was made as a consequence of enrolment. Research ethics board 
approval was obtained at participating centres, and individual patient consent was 
obtained. 
Data Collection 
Trained research nurses collected all data. Prior to study initiation, a centralized training 
meeting was held with the nurses to explain the purpose of the study and data collection 
methods. Standardized data collection forms were developed with input from the nurses. 
All data were entered centrally. After patient enrolment, data were evaluated for 
potential errors and missing values with subsequent prompting of the study centres for 
clarification. After the first year after study initiation, members of the steering committee 
formally liaised with each research nurse and local principal investigator by conference 
call. This allowed for potential data collection problems to be remedied further. 
The research nurses screened consecutive nephrology referrals, including both hospital 
and office based. Data collection forms were used to obtain data available both 1) before 
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the patient was seen by a nephrologist and 2) after nephrology assessment. Although the 
attending nephrologists were not directly involved in the data collection process, data 
sources included all those that the nephrologist would have access to: referral letter, 
outpatient I inpatient I emergency room department charts, computer records (laboratory 
and radiology data, prior consult I discharge letters, and so on) and patient interviews. 
Assessments done in the nephrologists' office or at a patient's bedside (eg routine 
urinalysis by using dipstick) would be available to the research nurse if documented in 
the consult letter or chart. The research nurse did not have access to data verbally 
communicated from referring physician to nephrologist that was not otherwise 
documented. Thus, missing data about prior investigations could be caused by those 1) 
not done; 2) done, but not available to the nephrologist; or 3) done and available to 
nephrologist through verbal communication, but not documented. 
Data collection included patient demographics, referral patterns (referring physician, time 
from referral to being seen, travel time and distance to nephrologist, and so on) as well as 
clinical, laboratory, and medication information. Treatment strategies, such as cardio-
renal risk-factor assessment and modification and anemia and mineral metabolism 
management before and during the first nephrology visit, were examined. The following 
definitions were used for data collection: coronary artery disease documented by history 
of san1e or intervention (angioplasty); left ventricular hypertrophy documented by 
echocardiogram; myocardial infarction documented by history and/or cardiac 
evaluations; cerebro-vascular accident documented by history and/or radiological 
documentation; peripheral vascular disease documented by history I physical examination 
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(e.g. claudication I pedal pulses) and/or documentation of investigation (e.g. angiogram); 
any non-specific bone disease documented by history, physical examination, laboratory 
results (including abnormal parathyroid hormone), and/or documentation of investigation 
(e.g. X-Ray, bone mineral density); bone pain by history; fracture documentation of 
spontaneous, non-traumatic fractures or fractures from any trauma. 
Availability of and use of additional services, including evaluation and treatment by 
allied health personnel, educational programs, and nutritional counselling, were 
documented at first encounter by using questionnaires. Educational programs were 
defined as those specifically targeting CKD issues (including what kidneys do, what 
CKD means, what dialysis means, lifestyle modification etc). They involved the patient 
and family (if requested) meeting with the educator, usually a specialized nurse, and may 
have also included a set of ancillary learning materials, such as books and video. 
Nutritional counselling included that which targeted CKD issues (low potassium and 
phosphate levels) and relevant co-morbid disease (salt restriction for hypertension I 
congestive heart failure, low fat diet etc). Because counselling could be provided by 
renal dieticians and may include other members of the team (nephrologist or nurse 
educator), data were collected for both types of encounters. Furthermore, resources were 
considered formal (versus informal) if they were part of a follow-up according to 
protocol with predetermined therapeutic goals specific to CKD. Finally, options for 
various team structures available at the participating centers were categorized as follows 
[8]: 
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Care delivered by a coordinated team dedicated to CKD: Nephrologists and allied health 
professionals (nurses, nurse educators, dieticians, social workers, and pharmacists) 
interact with the patient and each other as a formal multidisciplinary team. Although 
there were a number of different configurations because of funding and local health care 
system issues, for the purpose of this definition, a team was readily identifiable as 
dedicated (part or full time) to CKD care. Generally, there would be team rounds or 
meetings. Average duration of exposure of the patient to the team was approximately 1.5 
hours for the encounter. Additional details of the multi-disciplinary clinics also were 
described elsewhere [8, 10, 51]. 
Dedicated CKD care delivered outside of a coordinated team: The patient receives care 
by a professional or professionals from a CKD team dependent on the patient's need but 
without coordination or input by the entire team. 
Ad hoc CKD care: Allied health personnel(s) not affiliated or coordinated as a CKD team 
provide care to the patient when requested by the nephrologist on an "as needed" basis. 
Resource exposure was defined as first contact with an allied health care professional and 
I or nephrologist. Although all patients in this study were assessed by a nephrologist, it 
was possible that upon receiving a consult or referral, the nephrologist had the patient 
assessed by an allied health care professional or the CKD care team before seeing the 
patient him/herself. 
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Analysis 
Descriptive analyses are presented as mean ± standard deviation or median [with inter-
quartile range] depending on distribution. Because of variation in assays and reporting, 
some laboratory data are shown only as having been ordered or not (ie. specific values for 
results of parathyroid hormone and urinalysis are not given). Multiple linear regression 
was used to investigate independent predictors of wait-times. Variables for this model 
included demographics, referral source (inpatient, emergency department etc), referring 
physician specialty, patient distance and travel time, blood pressure, laboratory 
(creatinine, hemoglobin, albumin, urine studies) and co-morbidity (diabetes, 
hypertension, etc) data. 
4.3 Results 
Patient Characteristics at first encounter 
Four-hundred eighty-two incident CKD patients were enrolled from 13 Canadian centres. 
We report here only the data from the initial encounter. Follow up data will be analyzed 
and reported when available. No major differences in patient characteristics were 
apparent between sites; however, statistical comparisons were limited because of low 
nun1bers enrolled at individual centers. 
Table 4.1 lists demographic and clinical data at referral. Mean age ofthe cohort was 69.7 
years, with just more than 40% women and a majority of white patients. Two-thirds of 
the patients were retired, reflecting their age. Importantly, blood pressure was not 
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optimally controlled and patients were overweight. Of interest, more than 2% of patients 
were already enrolled in ongoing clinical trials before referral. 
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Table 4.1 Demographic and Clinical Data for Patients with CKD 
at the Time of First Referral to Nephrologists 
N 
Age (years) 
Gender(% Female) 
Race:(%) 
White 
Aboriginal 
Asian 
Filipino 
East Indian 
Black 
Latin American 
Employment Status(%) 
Retired 
Work > 35 hrs I week 
Work < 35 hrs I week 
Disability 
Unemployed 
Homemaker 
Other 
482 
69.7 ± 12.4 
42 
90 
3 
2 
2 
2 
0.4 
0.4 
68 
10 
3.5 
7 
4 
6.5 
2 
90 
Blood Pressure (mm Hg) 
Proteinuria > 0.5 g/day* (%) 
Weight (pounds) 
Body Mass Index (metric) 
Current Smoker (%) 
Patient in a Clinical Trial Before Referral (%) 
147 ± 25 / 76 ± 13 
13 
172 ± 37 
29 ± 6 
16 
2.3 
*Information on proteinuria status was documented before referral for only 64 patients 
(i .e. 8 of these has proteinuria > 0.5 g). Continuous Data expressed as Mean ± Standard 
Deviation 
Characteristics of Referral 
How the CKD patients were referred to Nephrologists and the plans for follow-up after 
the encounter is shown in Table 4.2. The majority of patients were referred by Family 
Physicians. Over 90% of patients were referred as outpatients and seen in the 
Nephrologists ' office or clinic. Patients' self-reported median distance from home to 
nephrologist was 9 miles (15 km) with 75% of patients within 40 miles (65 km)- travel 
times to nephrologist are concordant with these data. The median wait time from initial 
referral to first nephrologist visit was 43 days. Independent significant predictors of 
shorter wait-times (P < 0.05) were lower estimated GFR and inpatient referral. The 
estimated GFR did not change much over this waiting time. Patients were referred with a 
median estimated GFR of29 mL/min with 59% of patients referred at CKD Stage IV or 
V. Nephrologists planned to follow almost this entire cohort of patients in co-
management with the referring physician. 
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Table 4.2 Referral of CKD Patients to Nephrologists in Canada 
Referring physician (%) 
Family Physician 
Internal Medicine 
Cardiologist 
Endocrinologist 
Emergency Physician 
Other 
Location where referral or consultation originated(%) 
Outpatient I office I clinic 
Inpatient 
Emergency department 
Physical examination documented by referring 
physician (%) 
Location of first nephrology encounter (%) 
Nephrology office I clinic 
Hospital inpatient 
Emergency department 
Distance from patient to nephrologist (miles) 
One-way travel time to see nephrologist (min) 
Wait-time from referral to being seen (days) 
80 
5 
5 
4 
5 
92 
6 
2 
39 
95 
4 
9 [4, 40] 
25 [15, 60] 
43 [19, 74] 
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GFR* when referred (mL/min/1.73 m2) 
GFR* when seen by Nephrologist (mL/min/1.73 m2) 
Median Change in GFR * from referral to 
nephrologist visit 
CKD Stage at Encounter (%) 
II 
III 
IV 
v 
Plan for follow-up after encounter(%) 
Nephrology office I clinic 
Family physician 
Other 
29 ± 12 
27 [22, 36] 
29 ± 11 
27 [21, 35] 
- 0.3 [-4, 3] 
1.5 
39.5 
52 
7 
92 
7 
Continuous data are shown as mean± standard deviation or median [25th - 75th percentile] 
*Estimated by Abbreviated MDRD Study equation [152] 
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Burden of Illness at Referral 
Tables 4.3 and 4.4 list the burden of cardiac risk factors , cardiac disease and CKD 
complications already present at the encounter. Almost half the cohort had diabetes, 80% 
had hypertension and more than half had a smoking history. Of note, 31% of patients had 
established coronary artery disease and about 20% of patients had peripheral vascular 
disease, a previous myocardial infarction, and I or an episode of congestive heart failure. 
The reported symptoms of patients with cardiac disease listed in Table 4.4 describe this 
in more detail. One-fifth of patients had established non-specific bone disease or pain. 
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Table 4.3 Prevalence of Cardiac Disease, Cardiac Risk Factors and CKD Complications 
at First Nephrology Encounter 
Any history of smoking (%) 58 
Diabetes mellitus(%) 43 
Type II(% of those with diabetes) 87 
Hypertension(%) 80 
Cardiovascular Disease Co-Morbidities 
Coronary artery disease (%) 31 
Prior myocardial infarction(%) 20 
Prior coronary artery bypass grafting (%) 9 
Prior cardiac angioplasty (%) 7 
Congestive heart failure(%) 19 
Documented left ventricular hypertrophy(%) 7 
Prior cerebro-vascular accident(%) 9 
Peripheral vascular disease(%) 18 
Mineral Metabolism 
Any non-specific bone disease(%) 15 
Bone pain (%) 19 
Prior fracture in last 1 0 years (%) 4 
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Table 4.4 Reported Symptoms At First Nephrology Encounter for Patients With Cardiac 
Disease 
Heart failure- New York Heart Association classification(%) 
42 
II 
III 
IV 
41 
14 
3 
Angina- Canadian Cardiovascular Society classification(%) 
I 
II 
III 
IV 
v 
59 
24 
10 
4 
3 
Management Before the Encounter 
Table 4.5 shows laboratory data ordered by the referring physician and available for 
assessment by nephrologist at the time of referral. Data are shown as both numbers of 
tests available, as ordered by referring physician, and test result if available. Of interest, 
at the time of referral serum creatinine values were available for only 84% of patients, 
and hemoglobin values for 51%. Results of tests for albumin, lipids, iron, and mineral 
metabolism (serum calcium, phosphate and parathyroid hormone) were available for less 
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than a third of patients at the time of encounter. Of results that were available, mean 
hemoglobin level was 12.1 g/dL (121 g/L), and albumin level was 3.6 g/dL (36 giL). For 
patients with an available hemoglobin result and with latest results less than < 12 g/dL, 
results of iron studies were available for less than 20% of patients. As listed in Table 4.6, 
before the encounter, less than half of patients were being treated with ace inhibitor I 
angiotensin receptor blocker, and only 30% were being treated with acetylsalicylic acid 
or lipid medication. Furthermore, 11% of patients were administered non-steroidal anti-
inflammatory drugs (NSAIDs) or cyclooxygenase-II (COX-II) inhibitors. Specific 
interventions for proteinuria, previous myocardial infarction, dyslipidemia, and anemia 
are also listed. We were unable to examine data for mineral metabolism intervention 
(serum calcium, phosphate, and parathyroid hormone abnormalities and pharmaceutical 
intervention with phosphate binders or vitamin D analogs) because: a) so few patients 
had results for these tests available b) even fewer had results that were out of range (e. g. 
6 patients had serum phosphate > 1.8 mmol/L) and c) different parathyroid hormone 
assays made comparison impossible. 
Management at First Encounter 
Percentages of laboratory tests available to or subsequently ordered by the nephrologist 
are also shown in Table 4.5. Nephrologists had available or obtained the following 
further investigations in >70% of patients: hemoglobin, albumin, and calcium/phosphate. 
However, at first assessment nephrologists did not order laboratory testing of parathyroid 
hormone in 83% of patients, lipid profiles in > 50%, nor iron studies (of those with 
anemia) in 57%. Interestingly, urine studies (routine or 24 hour urinalysis) were not 
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ordered in 30%. Medication profiles after the encounter are also listed in Table 4.6. Data 
show that medical therapies after first nephrologist encounter were similar to those before 
(including NSAID and COX-II inhibitor use). Data about medications for proteinuria, 
previous myocardial infarction, dyslipidemia and anemia are based on information 
available to the nephrologist at the encounter. Use of iron, erythropoietin and calcium 
supplementation and I or phosphate binders increased at the first nephrology encounter, 
and 38% of patients with systolic blood pressure > 130 mmHg at referral had blood 
pressure medications added and/or doses increased (data not shown in table). 
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Table 4.5 Laborator~ Evaluation 
Tests with 
results available 
at first 
Nephrology 
Encounter 
N (%) Resultt 
Serum Creatinine (g/dL) 405 
2.4±0.9 
(84) 
Serum Urea (mg/dL) 261 
42±17 
(54) 
Hemoglobin (g/dL) 248 
12.1± 1.8 
(51) 
Serum Albumin (g/dL) 113 
3.6±0.6 
(23) 
Serum Bicarbonate 79 
26±4 
(mEq/L) (16) 
Serum Transferrin-Sat(%) 27 (6) 23±8 
Serum Ferritin (ng/mL) 45 (9) 52±35 
If Hemoglobin < 12 127 
g/dL (26) 
Serum Transferrin-Sat 
12 (9) 22±10 
(%) 
Tests Ordered by 
Nephrologist 
N (%) 
381 (79) 
344 (71) 
326 (68) 
317 (66) 
243 (50) 
167 (35) 
134 (28) 
212 (44) 
13 (6) 
Resultt 
2.4± 1.0 
45±25 
12.1±1.9 
3.7±0.5 
26±4 
20±9 
53±52 
22±7 
Tests with Results 
Available to 
Nephrologist after 
first patient encounter 
N (%) 
466 (97) 
41 2 (85) 
404 (84) 
368 (76) 
265 (55) 
185 (38) 
166 (34) 
53 (42) 
99 
Serum Ferritin 
(ng/mL) 
Serum Calcium (mg/dL) 
Serum Phosphate (mg/dL) 
Serum Parathyroid 
Hormone* 
Serum Cholesterol 
(mg/dL) 
Serum LDL (mg/dL) 
Serum HDL (mg/dL) 
Serum Triglyceride 
(mg/dL) 
Any urine Assessment 
Any Routine Urinalysis 
Any 24 Hour Urine 
Study 
23 
(18) 
110 
(23) 
87 
(18) 
14 (3) 
131 
(27) 
114 
(24) 
121 
(25) 
122 
(25) 
207 
(43) 
120 
(25) 
135 
(28) 
50±24 25 (12) 54±34 54(43) 
9.2±0.6 318 (66) 9.3±1.5 365 (76) 
4.0±1.1 301 (62) 3.9±0.9 344 (71) 
73 (15) 82 (17) 
205±54 I 06 (22) 197±50 205 (43) 
120±46 80 (17) 104±35 172 (36) 
50±35 83 (17) 46±23 181 (38) 
213±115 88 (18) 221± 177 187 (39) 
258 (54) 337 (70) 
190 (39) 254 (53) 
122 (25) 222 (46) 
100 
toata are shown as Mean ± Standard Deviation, *Serum Parathyroid Hormone obtained 
using different assays in various centres; LDL I HDL - Low I High Density Lipoprotein 
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Table 4.6 Patient Medication Profile Before and After first Encounter By Nephrologist 
% Taking Medication 
Before After Encounter 
Encounter 
Ace Inhibitor 36 40 
Angiotensin Receptor Blocker 12 10 
Ace Inhibitor or Angiotensin Receptor 46 46 
Blocker 
If Proteinuria > 0.5 g/day* 
Ace Inhibitor or Angiotensin Receptor 55 53 
Blocker 
Acetylsalicylic Acid 30 37 
Beta Blocker 32 30 
If Prior Myocardial Infarction* 
Acetylsalicylic Acid 41 58 
Beta Blocker 48 48 
Calcium Channel Blocker 31 35 
Non-Dihydropyridine 14 
Dihydropyridine 22 
Alpha Blocker 6 4 
Nitrate 14 15 
Diuretic 46 46 
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Any Lipid Medication 30 32 
If LDL > 97 mg/dL (2.5 mmol!L)* 38 40 
IfLDL > 135 mg/dL (3.5 mmol/L)* 49 52 
Statin 27 
Fibrate 6 
Other 2 
Iron Supplementation 6 14 
If Hemoglobin < 12 g/dL (120 g/L)* 10 23 
If Hemoglobin < 11 g/dL (II 0 g/L)* 16 27 
If Hemoglobin < 10 g/dL (1 00 g/L)* 22 41 
Erythropoietin 0 4 
IfHemoglobin < 12 g/dL (120 g/L)* 0 8 
If Hemoglobin < 11 g/dL (II 0 g/L)* 0 I3 
IfHemoglobin < 10 g/dL (100 g/L)* 0 19 
Calcium Supplementation I Phosphate Binder 6 18 
Calcium Supplementation 5 16 
Phosphate Binder 0.6 4 
Vitamin D Supplementation 3 4 
Vitamin B Supplementation 5 7 
Folate Supplementation 2 4 
NSAID or COX II Inhibitort 1 I II 
NSAID 7 7 
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---------------------------------
COX II Inhibitor 5 5 
*Data on disease or lab tests for proteinuria, myocardial infarction, dyslipidemia, anemia 
were those available to the Nephrologist before the encounter 
tNSAID: Non-steroidal anti-inflammatory; COX-II: cyclooxygenase-II inhibitor 
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Availability and Exposure to other Resources 
Table 4. 7 lists the resources available to patients at the participating centres, and the 
percentage of patients who got exposure in the different delivery settings at first 
encounter. Despite 86% of patients being treated at centers with availability of 
educational programs, nutritional counseling and allied health care professionals, a 
smaller number could actually take advantage by coming into contact with these 
resources. However, patient exposure to all resources increased to 92- 98% (data not 
shown) if the program had a formal structure with protocolized follow-up and 
predetermined goals for CKD care (e.g. exposure was driven by eGFR). 
Table 4.7 CKD resource availability and utilization at first encounter 
CKD Educational 
Program 
Nutritional 
Counselling** 
Dedicated CKD 
Multidisciplinary Team 
Nephrologist 
Nurse 
Social Worker 
Dietician 
Pharmacist 
Resource Patient Exposed to the Resource 
Available to the (%)* 
------------~_L ____________ _ 
Patient(%) Formal Informal 
86 7 3 
86 20 4 
83 10 0.4 
98 70 27 
86 36 11 
85 7 0.2 
85 19 2 
54 8 0.2 
*See text for details about Formal versus Informal Resources 
**includes counselling by dietician, nursing staff and I or physician 
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4.4 Discussion 
We describe a Canadian group of patients at their first encounter with nephrologists. 
Their treatments appear to be suboptimal before the encounter. Transmission of clinical 
information with the referral or consultation is limited. We further document the 
evaluation at the encounter and changes in medications. Further, we describe what 
additional resources and allied health care services are available to nephrologists and 
patients with CKD at our centers. The Canadian health care system is one of national 
universal health care coverage similar to that in Australia, the United Kingdom and parts 
of Europe where direct cost to the patient are not likely to result in underutilization. 
Physician services are free to patients at point of care and paid from government sources. 
All allied health care workers in this study were employed by the health care facilities 
and provided CKD care without charge to the patient. Similarly, patients do not have to 
pay for diagnostic assessments. However, patients may have to pay for their own 
outpatient pharmaceuticals either out of pocket or through private insurance. Provinces 
differ with respect to which patients groups can access various medications on a publicly 
funded formulary. In general, patients over 65 years of age or those receiving social 
welfare payments would be entitled to such access. In some jurisdictions (eg British 
Columbia and Ontario) patients with specific disease conditions ( eg anemia of kidney 
disease) may be entitled to access specific therapies (eg erythropoiesis stimulating 
agents). 
Our data reveals that relatively late nephrology referral persists in Canada despite 
attempts to address this issue [ 40]. In our study enrolment occurred just after the 
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Canadian CKD guidelines were published but before extensive uptake. The median wait 
time of 43 days for stage IV CKD may be reasonable given that the patients' estimated 
GFR did not decline very much, and the fact that lower estimated GFR predicted shorter 
wait times. Guidelines establishing wait time benchmarks for CKD referral do not 
currently exist, and further data would be required to determine these. 
More importantly, despite the burden of CVD illness in this cohort, there remained 
incomplete investigation of CKD, incomplete evaluation for CVD co-morbid diseases, 
and lack of complete application of proven effective therapies for cardiovascular disease 
and CKD co-morbidities. Indeed others have shown that prevalent CKD patients do not 
get adequate care [9, 164, 171, 172, 174-176] in keeping with documented 'therapeutic 
nihilism' that may exist in the approach to treatment of these patients [164, 174, 177-
179]. It is important to highlight this point given that Canadian nephrologists believe that 
CKD referral should occur at Stage III [180] and that nephrologists should represent the 
reference of CKD care. 
Other interesting points in this study are the descriptions of missing data or data not 
available to the nephrologists at the time of referral. This study was not designed to 
evaluate referring physicians' practices per seas their charts may not have been 
available- we thus cannot determine whether the investigations were not done versus 
done and not available. Both are important as the potential repeating of laboratory testing 
by the nephrologist in some cases may reflect a costly redundancy without benefit. Future 
studies should determine the amount of duplicate testing in this patient group, and define 
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better methods for information transfer. Currently there is no expectation regarding 
transmission of ' standard' information at time of referral to nephrologist: this may 
contribute to the variation seen in this study. Despite guidelines and education to Family 
Physicians, a widespread standard referral form with essential information (a tool to 
improve communication, reduce redundancies, and indirectly educate) does not exist. The 
potential improvements in care and cost savings of such a tool should be explored. 
Our data also demonstrates that there is variability in nephrology care; the reasons for this 
are not readily explained from the present study. It appears that at first visit nephrologists 
are intervening with CKD specific therapies (e.g. anemia therapies) but may not address 
the addition of renin angiotensin system blockade, reduction in proteinuria or 
cardiovascular risk profiles. Moreover, nephrologists are not discontinuing medications 
that may increase risk for both poor cardiovascular outcomes and progression of CKD 
(e.g. NSAIDs) [ 181]. There is also inconsistency amongst nephrologists in the initial 
evaluation 'panel' , which may further confuse referring physicians as to the necessity of 
evaluation in CKD. This study is unable to answer the question as to the proportion of the 
variability explained by patient or situational issues versus individual practice pattern. 
This would be the target of future studies. 
Weaknesses of this study include those inherent in its design and possible limitations of 
external validity. As a non-interventional study, the data collected were simply 
tabulations of information available at the first nephrology encounter. To our knowledge 
these patients and their characteristics are representative of those first encountered by 
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nephrologists across Canada; however we did not collect data in centres that were not 
participating, and regional differences cannot be ruled out. As this descriptive study did 
not directly question referring physicians nor nephrologists, other referral biases may 
exist. For example, physicians may be only referring patients that they consider 
"difficult" and have patients in their practice with similar GFR but that they are able to 
manage according to guidelines. As this study was conducted to understand the care of 
patients referred for CKD care, those with imminent dialysis initiation were excluded. 
This exclusion likely results in under-estimation of the problem. 
Furthermore, we cannot infer causes or to judge "appropriateness" in detail ( eg. reasons 
for not using angiotensin converting enzyme inhibitors). It is quite possible that 
interventions not implemented at the first encounter would be initiated later. Other non-
pharmacological interventions such as protein restriction or exercise counselling were 
also not captured. Finally, because the study was conducted prior to any creatinine 
standardization or calibration, some patients may have been misclassified. However, we 
chose a conservative cut-off for estimated GFR of 50 mL/min/1. 73m2 and the mean level 
of estimated GFR was well in the range of CKD stage III. 
Unique to this study are the findings of incomplete transmission of clinical information 
on patient evaluation and sub-optimal application of appropriate medical therapies by 
referring physicians, and after the first visit to a nephrologist. The current referral 
practice does not reflect a sophisticated understanding of the complexity of caring for 
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CKD patients by the referring physicians. Furthermore, there appears to be room for 
improvement in the care delivered by nephrologists at the first encounter. 
The resources available to nephrologists are variable, and irrespective of the variability 
the majority of patients do not access these resources at first visit. The data suggest that 
if the various resources are offered in a formal protocolized manner, patients are more 
likely to be exposed to them. Further analysis will explore the relationship between care 
resource exposure and outcomes. 
This study represents the first attempt to prospectively document and evaluate the care of 
CKD patients at the time of first nephrology encounter in a universal health care system. 
It enhances our understanding of the referral process and evaluates care patters to identify 
opportunities for improvement. Interventions to improve transmission of referral 
information implementation of comprehensive care plans should be the focus of future 
studies. Improved care with appropriate resources should ultimately improve patient 
outcomes. 
4.5 Addendum 
Further analysis of this cohort completed since original publication includes follow-up of 
clinical outcomes (unpublished data). After a median follow-up of28 [17, 41] months, 
78 (16%) patients died, 55 (11%) initiated kidney replacement therapy (KRT), 26 (5%) 
were discharged from nephrology care, and 38 (8%) were lost to follow-up. Significant 
univariate predictors of death were baseline age, history of cardiac disease, estimated 
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GFR, hemoglobin, and phosphate. Univariate predictors of a composite endpoint of 
death or KRT were baseline history of cardiac disease, estimated GFR, hemoglobin, 
albumin, calcium, phosphate, hypertension, and proteinuria. Multivariate Cox-
proportional hazards modeling revealed age (~=1.08 I year), initial phosphate ( ~=3.48 I 
mmol/L), and initial Hb (~= 1.02 I giL) as significant predictors for death. Baseline 
estimated GFR (~= 1 .07 I mL/min), history of cardiac disease(~= 3.6) and initial 
phosphate (~=6.5) and LDL (~=1.4 I mmol/L) were significant predictors for composite 
death or KRT. Only proteinuria was a significant predictor of estimated GFR decline in 
both univariate and multivariate linear regression modeling. 
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Chapter 5: Conclusion 
Ensuring that patients are adequately prepared for dialysis is no longer a sufficient 
primary goal of CKD care. In chapter 1 it was suggested that patient outcomes could be 
improved by intervening earlier in the course of CKD, and on many levels. Thus, the 
overall paradigm of CKD care appropriately changed to focus on the prevention of the 
progression of CKD in conjunction with the prevention of its concomitant morbidity and 
mortality. 
The question remains- how best to achieve these goals? The findings in Chapter 2 
suggest that substantial numbers of patients across Canada started dialysis with 
suboptimal clinical and laboratory parameters despite being previously followed by a 
nephrologist. The main limitations ofthe survey were inherent in its design. It was 
unable to examine what happened to these patients during their prior CKD care (i.e. those 
patients not progressing were not in the study population). It may be possible that 
nephrologists were successful with other goals: a) preventing progression, and thus not 
having patients progress to require dialysis therapy; or b) preventing other co-morbidities 
that accompany CKD. Furthermore, an alternate explanation for some of the findings 
would include the possibility that, despite the best intentions of the nephrology care team, 
patients may have declined recommendations (e.g. refused to start dialysis earlier) or had 
an unexpected precipitating event (e.g. myocardial infarction or infection) contributing to 
the poor clinical and laboratory parameters. Finally, quality of life, an important aspect 
from the patients' perspective, was not exan1ined formally. Despite these limitations, the 
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study' s findings provide useful baseline information that may be used for comparison 
across the country. 
Similar limitations apply to the study presented in Chapter 3. CKD care and survival 
prior to dialysis start was not examined formally. A second limitation includes a 
potential bias associated with the type of patient that is willing to attend these 
multidisciplinary clinics. There may be some inherent patient characteristic (e.g. attitude, 
interest, motivation, etc) that would make them more likely to do better (e.g. more 
compliant with medications). The study's strength lies in its ability to examine an 
important clinical outcome- survival. However, the optimal way to address this question 
of how to best care for CKD patients may be through a randomized control trial. 
Finally, Chapter 4 suggests there is room for improvement in evaluation and treatment of 
CKD patients before they reach dialysis. In fact, it may in part explain the findings of 
Chapter 2. As discussed previously, the main limitations of the study include external 
validity and referral bias. Finally, the inability to make causal inferences reinforces the 
need for further studies to determine if intervention in phosphate and haemoglobin 
control, for example, will translate into better outcomes in this population. 
Although there appears to be evidence to support the idea that a multidisciplinary care 
model would be appropriate for CKD care, barriers to the implementation of MDC 
models remain before embracing this fully . The first issue is cost. Team's staff salaries 
and infrastructure must be taken into account within a complex system with other 
113 
competing issues (e.g. cancer care and wait-times). Data from a randomized control trial 
of CKD care supporting the effectiveness of a MDC model is necessary before endorsing 
this type of model as a national recommendation. The study would also need to 
incorporate some form of economic analysis before governments or other health care 
payers would be willing to make this a fiscal priority. Another barrier would be 
nephrology buy-in as this would mean a paradigm shift for many nephrologists accepting 
that there may be a more optimal method for CKD care. However, overcoming the 
barrier of changing physician practice may be made easier through further study and 
education. Of course this must not only include the issue of CKD care itself, but also 
research into optimal ways of changing physician practice. Patient and family buy-in 
would also be required. Even if it was known that this multidisciplinary care model was 
best for CKD care, the team may not be able to help those patients who are just not 
interested. 
A further important issue in Canada is access to care in general. Given the country's low 
population density, with a significant proportion of the population living in rural areas, 
even access to family physicians is a potential barrier to care and would contribute to low 
or late CKD referral. Other practical difficulties also arise such as the physical distance 
between where patients live and where specialist care exists. This not only entails the 
time for travel, but must also include patient and family travel costs. 
Other questions remain about CKD care. These include how early should specific care 
begin or what aspects of nephrology care should occur when (i.e. at the first nephrology 
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encounter or later)? Furthermore, not all CKD care may be so "complex" to necessitate a 
multidisciplinary care model and may not benefit or be relevant for patients that choose 
conservative management (i.e. no dialysis). Finally, it is not clear where in the health 
system certain issues should be dealt with (e.g. lipid or diabetes management). Many 
would argue that some of these should be the focus of primary versus specialist care. 
Indeed, given that a significant number of CKD patients a) have already had a 
cardiovascular event prior to referral, b) are referred on inadequate cardiovascular risk 
reduction therapy, and c) may be more likely to die from cardiovascular disease then 
progress to dialysis, it may be more important and appropriate to focus health care efforts 
on improving overall primary and secondary cardiovascular care independent ofCKD. 
Regardless, a main issue should be a focus on communication and integration of care. 
Overall, this thesis incorporates novel data at various points along the spectrum of CKD 
care whereby patient care might be improved. However, nephrologists alone may not be 
adequate for this chronic disease care model. Data herein should also allow for 
nephrology programs to focus on improved CKD care along different points of the CKD 
spectrum. For example, setting continuous quality improvement targets for access 
placement prior to dialysis, or haemoglobin target achievement for late stage CKD. 
Earlier along the course of disease it might be more appropriate to examine practice with 
respect to blood pressure targets or medication review. Centres with available fiscal and 
staffing resources have already been incorporating some aspects of this model into their 
CKD care program. Despite this, enough equipoise exists such that randomized control 
trials are still needed to address some of these questions in CKD care. 
115 
References: 
1. Kiberd BA, Clase CM: Cumulative risk for developing end-stage renal disease in 
the US population. JAm Soc Nephro/13:1635-1644, 2002 
2. USRDS: the united states renal data system. American journal of kidney diseases 
: the official journal of the National Kidney Foundation 42:1-230, 2003 
3. Stigant C, Stevens L, Levin A: Nephrology: 4. Strategies for the care of adults 
with chronic kidney disease. CMAJ 168:1553-1560, 2003 
4. Levin A: The need for optimal and coordinated management of CKD. Kidney Int 
Suppl:S7-10, 2005 
5. Levin A: Consequences oflate referral on patient outcomes. Nephrol Dial 
Transplant15 Suppl3 :8-13, 2000 
6. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic 
renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. 
Am J Kidney Dis 30:S 192-240, 1997 
7. Muntner P, He J, Hamm L, Loria C, Whelton PK: Renal insufficiency and 
subsequent death resulting from cardiovascular disease in the United States. JAm 
Soc Nephrol 13:745-753, 2002 
8. Curtis B, Levin A: The Role of the Chronic Kidney Disease Clinic, in Chronic 
Kidney Disease, Dialysis, and Transplantation: A Companion to Brenner and 
Rector's The Kidney, edited by Pereira B, Sayegh M, Blake P, (ed 2) ed, 
Philidelphia, Elsevier Saunders, 2005, pp 71-85 
9. Curtis BM, Barret BJ, Jindal K, Djurdjev 0, Levin A, Barre P, Bernstein K, Blake 
P, Carlisle E, Cartier P, Clase C, Culleton B, Deziel C, Donnelly S, Ethier J, Fine 
A, Ganz G, Goldstein M, Kappel J, Karr G, Langlois S, Mendelssohn D, 
Muirhead N, Murphy B, Pylpchuk G, Toffelmire E: Canadian survey of clinical 
status at dialysis initiation 1998-1999: a multicenter prospective survey. Clin 
Nephrol 58:282-288, 2002 
10. Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev 0 , Levin A: 
The short- and long-term impact of multi-disciplinary clinics in addition to 
standard nephrology care on patient outcomes. Nephrol Dial Transplant 20: 14 7-
154,2005 
11. Curtis BM, Barrett BJ, Djurdjev 0, Singer J, Levin A: Evaluation and treatment 
of CKD patients before and at their first nephrologist encounter in Canada. Am J 
Kidney Dis 50:733-742,2007 
12. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen 0: Multifactorial 
intervention and cardiovascular disease in patients with type 2 diabetes. N Eng! J 
Med 348:383-393, 2003 
13. Gaede P, Vedel P, Parving HH, Pedersen 0: Intensified multifactorial 
intervention in patients with type 2 diabetes mellitus and microalbuminuria: the 
Stenotype 2 randomised study. Lancet 353 :617-622, 1999 
14. Jain A, Mills P, Nunn LM, Butler J, Luddington L, Ross V, Cliffe P, 
Ranjadayalan K, Tirnmis AD: Success of a multidisciplinary heart failure clinic 
for initiation and up-titration of key therapeutic agents. Eur J Heart Fai/7:405-
410,2005 
116 
15. Ducharme A, Doyon 0, White M, Rouleau JL, Brophy JM: Impact of care at a 
multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ 
173:40-45, 2005 
16. McDonald K, Ledwidge M, Cahill J, Quigley P, Maurer B, Travers B, Ryder M, 
Kieran E, Timmons L, Ryan E: Heart failure management: multidisciplinary care 
has intrinsic benefit above the optimization of medical care. J Card Fail8: 142-
148, 2002 
17. McAlister FA, StewartS, Ferrua S, McMurray JJ: Multidisciplinary strategies for 
the management of heart failure patients at high risk for admission: a systematic 
review of randomized trials. JAm Col! Cardiol44:810-819, 2004 
18. McAlister FA, Lawson FM, Teo KK, Armstrong PW: A systematic review of 
randomized trials of disease management programs in heart failure. Am J Med 
110:378-384,2001 
19. Coresh J, WeiGL, McQuillan G, Brancati FL, Levey AS, Jones C, Klag MJ: 
Prevalence of high blood pressure and elevated serum creatinine level in the 
United States: findings from the third National Health and Nutrition Examination 
Survey (1988-1994). Arch intern Med 161:1207-1216, 2001 
20. Goeree R, Manalich J, Grootendorst P, Beecroft ML, Churchill DN: Cost analysis 
of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 
18:455-464, 1995 
21. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C: Cost 
analysis of ongoing care of patients with end-stage renal disease: the impact of 
dialysis modality and dialysis access. Am J Kidney Dis 40:611-622, 2002 
22. Ruggenenti P, Gambara V, Perna A, Bertani T, Remuzzi G: The nephropathy of 
non-insulin-dependent diabetes: predictors of outcome relative to diverse patterns 
of renal injury. JAm Soc Nephrol9:2336-2343, 1998 
23. Biesenbach G, Janko 0, Zazgornik J: Similar rate of progression in the predialysis 
phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9: 1097-
1102, 1994 
24. Perneger TV, Brancati FL, Whelton PK, Klag MJ: End-stage renal disease 
attributable to diabetes mellitus. Ann Intern Med 121 :912-918, 1994 
25. Marcantoni C, Jafar TH, Oldrizzi L, Levey AS, Maschio G: The role of systemic 
hypertension in the progression of nondiabetic renal disease. Kidney Int Suppl 
75 :S44-48, 2000 
26. Perry HM, Jr. , Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz 
DW, Carmody SE: Early predictors of 15-year end-stage renal disease in 
hypertensive patients. Hypertension 25:587-594, 1995 
27. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: 
The effects of dietary protein restriction and blood-pressure control on the 
progression of chronic renal disease. Modification of Diet in Renal Disease Study 
Group. N Eng! J Med 330:877-884, 1994 
28. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, 
Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the 
progression of renal disease. The Modification of Diet in Renal Disease Study. 
Ann intern Med 123:754-762, 1995 
117 
29. Oldrizzi L, Rugiu C, DeBiase V, Maschio G: The place of hypertension among 
the risk factors for renal function in chronic renal failure. Am J Kidney Dis 
21 :119-123, 1993 
30. He J, Whelton PK: Elevated systolic blood pressure as a risk factor for 
cardiovascular and renal disease. J Hypertens Suppl 17:S7-13, 1999 
31. Walser M: Progression of chronic renal failure in man. Kidney Int 37:1195-1 210, 
1990 
32. Nolin L, Courteau M: Management of IgA nephropathy: evidence-based 
recommendations. Kidney Int Suppl 70:S56-62, 1999 
33 . Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers 
NL, Teschan PE: Predictors of the progression of renal disease in the 
Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997 
34. Keane WF: Proteinuria: its clinical importance and role in progressive renal 
disease. Am J Kidney Dis 35:S97-105, 2000 
35. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D: 
Cardiovascular disease and mortality in a community-based cohort with mild 
renal insufficiency. Kidneyint 56:2214-2219, 1999 
36. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. Am J Kidney Dis 39 (2 Suppl 2), 2002 
37. Stack AG: Impact oftiming of nephrology referral and pre-ESRD care on 
mortality risk among new ESRD patients in the United States. Am J Kidney Dis 
41:310-318, 2003 
38. Kinchen KS, Sadler J, Fink N, Brockmeyer R, Klag MJ, Levey AS, Powe NR: 
The timing of specialist evaluation in chronic kidney disease and mortality. Ann 
Intern Med 137:479-486, 2002 
39. McLaughlin K, Manns B, Culleton B, Donaldson C, Taub K: An economic 
evaluation of early versus late referral of patients with progressive renal 
insufficiency. Am J Kidney Dis 3 8: 1122-1128, 2001 
40. Mendelssohn DC, Barrett BJ, Brownscombe LM, Ethier J, Greenberg DE, Kanani 
SD, Levin A, Toffelmire EB: Elevated levels of serum creatinine: 
recommendations for management and referral. CMAJ 161 :413-417, 1999 
41. McClellan WM, Knight DF, Karp H, Brown WW: Early detection and treatment 
of renal disease in hospitalized diabetic and hypertensive patients: important 
differences between practice and published guidelines. Am J Kidney Dis 29:368-
375, 1997 
42. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ: Prevalence of and 
factors associated with suboptimal care before initiation of dialysis in the United 
States. JAm Soc Nephro/10:1793-1800, 1999 
43 . Levin A, Djurdjev 0 , Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, 
Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in 
patients with chronic kidney disease: getting to the heart of the matter. Am J 
Kidney Dis 38:1398-1407, 2001 
44. Balas EA, Weingarten S, Garb CT, Blumenthal D, Boren SA, Brown GD: 
Improving preventive care by prompting physicians. Arch Intern Med 160:301-
308, 2000 
118 
45. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, Isham 
G, Snyder SR, Carande-Kulis VG, Garfield S, Briss P, McCulloch D: The 
effectiveness of disease and case management for people with diabetes. A 
systematic review. Am J Prev Med 22:15-38, 2002 
46. Harris DE, Record NB, Gipson GW, Pearson TA: Lipid lowering in a 
multidisciplinary clinic compared with primary physician management. Am J 
Cardiol 81 :929-933, 1998 
47. Vliet Vlieland TP, Breedveld FC, Hazes JM: The two-year follow-up of a 
randomized comparison of in-patient multidisciplinary team care and routine out-
patient care for active rheumatoid arthritis. Br J Rheumato/36:82-85 , 1997 
48. Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes 
JM: A randomized clinical trial of in-patient multidisciplinary treatment versus 
routine out-patient care in active rheumatoid arthritis. Br J Rheumato/35:475-
482, 1996 
49. Prier A, Berenbaum F, Karneff A, Molcard S, Beauvais C, Durnontier C, Sautet 
A, Miralles MP, Peroux JL, Kaplan G: Multidisciplinary day hospital treatment of 
rheumatoid arthritis patients. Evaluation after two years. Rev Rhum Eng! Ed 
64:443-450, 1997 
50. Gabel M, Hilton NE, Nathanson SD: Multidisciplinary breast cancer clinics. Do 
they work? Cancer 79:2380-2384, 1997 
51. Levin A, Lewis M, Mortiboy P, Faber S, Hare I, Porter EC, Mendelssohn DC: 
Multidisciplinary predialysis programs: quantification and limitations of their 
impact on patient outcomes in two Canadian settings. Am J Kidney Dis 29:533-
540, 1997 
52. Klang B, Bjorvell H, Berglund J, Sundstedt C, Clyne N: Predialysis patient 
education: effects on functioning and well-being in uraemic patients. J Adv Nurs 
28:36-44, 1998 
53. Rasgon SA, Chemleski BL, Ho S, Widrow L, Yeoh HH, Schwankovsky L, Idroos 
M, Reddy CR, Agudelo-Dee L, James-Rogers A, Butts E: Benefits of a 
multidisciplinary predialysis program in maintaining employment among patients 
on home dialysis. Adv Per it Dia/12: 132-135, 1996 
54. Harris LE, Luft FC, Rudy DW, Kesterson JG, Tierney WM: Effects of 
multidisciplinary case management in patients with chronic renal insufficiency. 
AmJ Med 105:464-471, 1998 
55. Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C, Marwick TH: Increased 
targeting of cardiovascular risk factors in patients with chronic kidney disease 
does not improve atheroma burden or cardiovascular function. Am Heart J 
151:745-753, 2006 
56. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new 
paradigm. Am J Kidney Dis 35:S117-131 , 2000 
57. Klahr S, Schreiner G, Ichikawa 1: The progression of renal disease. N Eng! J Med 
318:1657-1666, 1988 
58. Loveman E, Cave C, Green C, Royle P, Dunn N, Waugh N: The clinical and cost-
effectiveness of patient education models for diabetes: a systematic review and 
economic evaluation. Health Techno! Assess 7:iii, 1-190, 2003 
11 9 
59. Latos D, Schatell D: The nephrologist's critical role in patient education. Adv Ren 
Replace Ther 10:146-149,2003 
60. Wright SP, Walsh H, Ingley KM, Muncaster SA, Gamble GD, Pearl A, Whalley 
GA, SharpeN, Doughty RN: Uptake of self-management strategies in a heart 
failure management programme. Eur J Heart Fai/5:371-380, 2003 
61. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. , 
Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ: The Seventh 
Report of the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure: the INC 7 report. Jama 289:2560-2572, 2003 
62. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, 
Douglas J, Hsueh W, Sowers J : Preserving renal function in adults with 
hypertension and diabetes: a consensus approach. National Kidney Foundation 
Hypertension and Diabetes Executive Committees Working Group. Am J Kidney 
Dis 36:646-661, 2000 
63. Meltzer S, Leiter L, Daneman D, Gerstein HC, LauD, Ludwig S, Yale JF, 
Zinman B, Lillie D: 1998 clinical practice guidelines for the management of 
diabetes in Canada. Canadian Diabetes Association. CMAJ 159 Suppl 8:S1-29, 
1998 
64. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, 
Floras JS, Haynes RB, Honos G, Leenen FH, Leiter LA, Logan AG, Myers MG, 
Spence JD, Zarnke KB: 1999 Canadian recommendations for the management of 
hypertension. Task Force for the Development of the 1999 Canadian 
Recommendations for the Management ofHypertension. CMAJ 161 Suppl12:S1-
17, 1999 
65 . Tight blood pressure control and risk of macrovascular and microvascular 
complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study 
Group. Bmj 317:703-713, 1998 
66. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard 
J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering 
and low-dose aspirin in patients with hypertension: principal results of the 
Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. 
Lancet351:1755-1762, 1998 
67. Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control 
on diabetic microvascular complications in patients with hypertension and type 2 
diabetes. Diabetes Care 23 Suppl 2:B54-64, 2000 
68. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, 
Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and 
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng! 
J Med345:861-869, 2001 
69. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins 
RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist 
irbesartan in patients with nephropathy due to type 2 diabetes. N Eng! J Med 
345:851-860,2001 
70. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro 
AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-
120 
stage renal disease in patients with type 2 diabetes and nephropathy: the 
RENAAL study. Kidney Int 63:1499-1507, 2003 
71 . Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, Redaelli 
B, Giangrande A: Proteinuria and blood pressure as causal components of 
progression to end-stage renal failure. Northern Italian Cooperative Study Group. 
Nephrol Dial Transplant 11 :461-467, 1996 
72. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular 
filtration rate and risk of terminal renal failure in proteinuric, non-diabetic 
nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in 
Nefrologia). Lancet 349:1857-1863, 1997 
73. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-
converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study 
Group. N Eng! J Med329:1456-1462, 1993 
74. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing 
effect of angiotensin-converting enzyme inhibition on plasma creatinine and on 
proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-
581 , 1993 
75. Philipp T, AnlaufM, Distler A, Holzgreve H, Michaelis J, Wellek S: 
Randomised, double blind, multi centre comparison of hydrochlorothiazide, 
atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the 
HANE study. HANE Trial Research Group. Bmj 315:154-159, 1997 
76. Estacio RO, Jeffers BW, Hiatt WR, BiggerstaffSL, Gifford N, Schrier RW: The 
effect of nisoldipine as compared with enalapril on cardiovascular outcomes in 
patients with non-insulin-dependent diabetes and hypertension. N Eng! J Med 
338:645-652, 1998 
77. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of 
angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes 
mellitus. A 7-year follow-up study. Arch Intern Med 156:286-289, 1996 
78. Giatras I, Lau J, Levey AS: Effect of angiotensin-converting enzyme inhibitors on 
the progression of nondiabetic renal disease: a meta-analysis of randomized trials. 
Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study 
Group. Ann Intern Med 127:337-345, 1997 
79. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal 
function and requirement for dialysis in chronic nephropathy patients on long-
term ran1ipril : REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in 
Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1 252-1256, 
1998 
80. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril 
to attenuate decline in renal function in normotensive, normoalbuminuric patients 
with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 
128:982-988, 1998 
81. Jacobsen P, Andersen S, Jensen BR, Parving HH: Additive effect of ACE 
inhibition and angiotensin II receptor blockade in type I diabetic patients with 
diabetic nephropathy. J Am Soc Nephro/14 :992-999, 2003 
12 1 
82. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a 
predictor of cardiovascular outcomes and the impact of ramipril : the HOPE 
randomized trial. Ann Intern Med 134:629-636, 2001 
83 . Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, 
Schneider KA: Prognostic value of serum creatinine and effect of treatment of 
hypertension on renal function. Results from the hypertension detection and 
follow-up program. The Hypertension Detection and Follow-up Program 
Cooperative Group. Hypertension 13:180-93, 1989 
84. Kannel WB, Stampfer MJ, Castelli WP, Verter J: The prognostic significance of 
proteinuria: the Framingham study. Am Heart J 108:1347-1352, 1984 
85. Schmitz A, Vaeth M: Microalbuminuria: a major risk factor in non-insulin-
dependent diabetes. A I 0-year follow-up study of 503 patients. Diabet Med 
5:126-134, 1988 
86. Curtis BM, Parfrey PS: How can the cardiac death rate be reduced in dialysis 
patients? Semin Dial 15:22-24, 2002 
87. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular 
hypertrophy in the predialysis population: identifying opportunities for 
intervention. Am J Kidney Dis 27:347-354, 1996 
88. Rigatto C, Foley RN, Kent GM, Guttmann R, Parfrey PS: Long-term changes in 
left ventricular hypertrophy after renal transplantation. Transplantation 70:570-
575, 2000 
89. Rigatto C, Foley R, Jeffery J, Negrijn C, Tribula C, Parfrey P: 
Electrocardiographic left ventricular hypertrophy in renal transplant recipients: 
prognostic value and impact of blood pressure and anemia. JAm Soc Nephrol 
14:462-468, 2003 
90. Rigatto C, Parfrey P, Foley R, Negrijn C, Tribula C, Jeffery J: Congestive heart 
failure in renal transplant recipients: risk factors, outcomes, and relationship with 
ischemic heart disease. JAm Soc Nephrol 13: I 084-1090, 2002 
91 . Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ: Cardiovascular 
disease after renal transplantation. JAm Soc Nephrol7: 158-165, 1996 
92. Controlling the epidemic of cardiovascular disease in chronic renal disease: What 
do we know? What do we need to know? Where do we go from here? Special 
report from the National Kidney Foundation Task Force on Cardiovascular 
Disease. Am J Kidney Dis 32:Sl-199, 1998 
93 . Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular 
disease in chronic renal disease. Am J Kidney Dis 32: S 112-119, 1998 
94. Parfrey (Editor) PS: Cardiac Disease in Chronic Uremia: uremia related risk 
factors . Seminars In Dialysis 12:61-132, 1999 
95. Levin A: How should anaemia be managed in pre-dialysis patients? Nephrol Dial 
Transplant 14 Suppl2:66-74, 1999 
96. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess 
E, Jindal K, Barrett B, Singer J, Djurdjev 0: Left ventricular mass index increase 
in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-
134, 1999 
97. Harnett JD, Kent GM, Foley RN, Parfrey PS: Cardiac function and hematocrit 
level. Am J Kidney Dis 25:S3-7, 1995 
122 
98. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of 
commonly measured variables and an evaluation of death rate differences 
between facilities. Am J Kidney Dis 15:458-482, 1990 
99. Madore F, Lowrie EG, Brugnara C, Lew NL, Lazarus JM, Bridges K, Owen WF: 
Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am 
Soc Nephro/8 :1921-1929, 1997 
100. Silverberg D, Blum M, Peer G, Iaina A: Anemia during the predialysis period: A 
key to cardiac damage in renal failure. Nephron 80:1-5, 1998 
101. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular 
hypertrophy in dialysis patients following correction of anemia with recombinant 
human erythropoietin. Can J Cardia! 6:1-4, 1990 
102. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with 
erythropoietin usage and patient outcomes. Am J Kidney Dis 32:S 133-141 , 1998 
103. Levin A: Anaemia in the patient with renal insufficiency: documenting the impact 
and reviewing treatment strategies. Nephrol Dial Transplant 14:292-295, 1999 
104. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, McCready WG, 
Muirhead N, Weir RV: Clinical practice guidelines for the management of anemia 
coexistent with chronic renal failure. Canadian Society ofNephrology. J Am Soc 
Nephrol 10 Suppl 13 :S292-296, 1999 
105. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, 
Segner A: European best practice guidelines 9-13 : anaemia management. Nephrol 
Dial Transplant 15 Suppl 4:33-42, 2000 
106. Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular 
disease in chronic renal failure. Kidney Int 56:383-392, 1999 
I 07. Fournier A, Aparicio M: [Letter to the authors of the "Recommendations for 
clinical practice" concerning the prevention of renal osteodystrophy before extra-
renal purification]. Nephrologie 19:129-130, 1998 
108. Nordal KP, Dahl E, Halse J, Attramadal A, Flatmark A: Long-term low-dose 
calcitriol treatment in predialysis chronic renal failure: can it prevent 
hyperparathyroid bone disease? Nephrol Dial Transplant 10:203-206, 1995 
109. Combe C, Aparicio M: Phosphorus and protein restriction and parathyroid 
function in chronic renal failure. Kidney Int 46:1381-1386, 1994 
110. Hakim RM, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 
21 : 125-13 7, I 993 
111 . Churchill ON: An evidence-based approach to earlier initiation of dialysis. Am J 
Kidney Dis 30:899-906, 1997 
112. Culp K, Flanigan M, Lowrie EG, Lew N, Zimmerman B: Modeling mortality risk 
in hemodialysis patients using laboratory values as time-dependent covariates. Am 
J Kidney Dis 28:741-746, 1996 
113. Kasiske BL, Lakatua JD, Ma JZ, Louis TA: A meta-analysis of the effects of 
dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 
31 :954-961 ' 1998 
114. Fouque D, Wang P, Laville M, Boissel JP: Low protein diets delay end-stage 
renal disease in non diabetic adults with chronic renal failure. Cochrane Database 
Syst Rev:CDOO 1892, 2000 
123 
115. Waugh NR, Robertson AM: Protein restriction for diabetic renal disease. 
Cochrane Database Syst Rev:CD002181 , 2000 
116. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, 
National Kidney Foundation. Am J Kidney Dis 35:S1-140, 2000 
117. DaRoza G, Loewen A, Djurdjev 0 , Love J, Kempston C, Burnett S, Kiaii M, 
Taylor PA, Levin A: Stage of chronic kidney disease predicts seroconversion after 
hepatitis B immunization: earlier is better. Am J Kidney Dis 42:1184-1192, 2003 
118. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary 
prevention of cardiovascular events in persons with mild chronic renal 
insufficiency. Ann Intern Med 138:98-104,2003 
119. Sever PS, DahlofB, PoulterNR, Wedel H, Beevers G, Caulfield M, Collins R, 
Kjeldsen SE, Kristinsson A, Mcinnes GT, Mehlsen J, Nieminen M, O'Brien E, 
Ostergren J: Prevention of coronary and stroke events with atorvastatin in 
hypertensive patients who have average or lower-than-average cholesterol 
concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid 
Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 
361:1149-1158,2003 
120. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 
20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-
22, 2002 
121. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int 
Suppl:S207-210, 2003 
122. Frohlich J, Fodor G, McPherson R, Genest J, Langner N: Rationale for and 
outline of the recommendations of the Working Group on Hypercholesterolemia 
and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health 
Canada. Can J Cardio/14 Suppl A:17 A-21A, 1998 
123. Summary ofthe second report ofthe National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel II) . Jama 269:3015-3023, 1993 
124. The effect of intensive treatment of diabetes on the development and progression 
of long-term complications in insulin-dependent diabetes mellitus. The Diabetes 
Control and Complications Trial Research Group. N Engl J Med 329:977-986, 
1993 
125. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes 
(UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-
853, 1998 
126. Retinopathy and nephropathy in patients with type 1 diabetes four years after a 
trial of intensive therapy. The Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Research Group. 
N Engl J Med 342:381-389, 2000 
127. Regalado M, Yang S, Wesson DE: Cigarette smoking is associated with 
augmented progression of renal insufficiency in severe essential hypertension. Am 
J Kidney Dis 35:687-694, 2000 
128. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, 
Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, 
124 
Zucchelli P: Smoking as a risk factor for end-stage renal failure in men with 
primary renal disease. Kidney Int 54:926-931, 1998 
129. Rasgon S, Schwankovsky L, James-Rogers A, Widrow L, Glick J, Butts E: An 
intervention for employment maintenance among blue-collar workers with end-
stage renal disease. Am J Kidney Dis 22:403-412, 1993 
130. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, Muirhead N: A 
study of the quality of life and cost-utility of renal transplantation. Kidney Int 
50:235-242, 1996 
131. Ifudu 0 , Dawood M, Home! P, Friedman EA: Excess morbidity in patients 
starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 
28:841-845, 1996 
132. Jungers P, Zingraff J, Albouze G, Chauveau P, Page B, Hannedouche T, Man 
NK: Late referral to maintenance dialysis: detrimental consequences. Nephrol 
Dial Transplant 8:1089-1093, 1993 
133. Schmidt RJ, Domico JR, Sorkin MI, Hobbs G: Early referral and its impact on 
emergent first dialyses, health care costs, and outcome. Am J Kidney Dis 32:278-
283, 1998 
134. Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A: Clinical 
practice guidelines for vascular access. Canadian Society pfNephrology. J Am 
Soc Nephrol10 Suppl13:S297-305, 1999 
135. Hakim RM, Lazarus JM: Initiation of dialysis. JAm Soc Nephrol6:1319-1328, 
1995 
136. Bonomini V: Early dialysis 1979. Nephron 24:157-160, 1979 
13 7. Bonomini V, Baldrati L, Stefoni S: Comparative cost/benefit analysis in early and 
late dialysis. Nephron 33:1-4, 1983 
138. Bonomini V, Feletti C, Scolari MP, Stefoni S: Benefits of early initiation of 
dialysis. Kidney Int Suppl17:S57-59, 1985 
139. Bonomini V, Vangelista A, Stefoni S: Early dialysis in renal substitutive 
progran1s. Kidney Int Sup pi: S 112-116, 1978 
140. Churchill DN, Blake PG, Jindal KK, Toffelmire EB, Goldstein MB: Clinical 
practice guidelines for initiation of dialysis. Canadian Society of Nephrology. J 
Am Soc Nephro/10 Suppl13:S289-291 , 1999 
141. Rao M, Kausz AT, Mitchell D, Ratican SH, Lin F, Burrows-Hudson S, Port F, 
Pereira BJ: The Study of Treatment for Renal Insufficiency: Data and Evaluation 
(STRIDE), a national registry of chronic kidney disease. Semin Dial 15:366-369, 
2002 
142. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, 
Franklin-Becker ED, Go AS, Hm LL, He J, Hostetter T, Hsu CY, Jamerson K, 
Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER, 3rd, Muntner P, 
Ojo AO, Rahman M, Townsend RR, Wright JT: The Chronic Renal Insufficiency 
Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol14:S 148-153, 
2003 
143. Ohmit SE, Flack JM, Peters RM, Brown WW, Grimm R: Longitudinal Study of 
the National Kidney Foundation's (NKF) Kidney Early Evaluation Program 
(KEEP). J Am Soc Nephro/14:S117-1 21, 2003 
125 
I44. Ismail N, Neyra R, Hakim R: The medical and economical advantages of early 
referral of chronic renal failure patients to renal specialists. Nephrol Dial 
Transplant I3 :246-250, I998 
145. Arora P, Obrador GT, Ruthazer R, Kausz AT, Meyer KB, Jenuleson CS, Pereira 
BJ: Prevalence, predictors, and consequences of late nephrology referral at a 
tertiary care center. JAm Soc Nephrol1 0:1281-1286, 1999 
146. Ifudu 0 , Dawood M, Homel P, Friedman EA: Timing of initiation of uremia 
therapy and survival in patients with progressive renal disease. Am J Nephrol 
I8:193-198, 1998 
147. Obrador GT, Pereira BJ: Early referral to the nephrologist and timely initiation of 
renal replacement therapy: a paradigm shift in the management of patients with 
chronic renal failure. Am J Kidney Dis 31:398-417, 1998 
148. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, Handa SP, 
Jindal KK, Kjellstrand CM, Levin A, Mandin H, Muirhead N, Richardson RM: 
Prediction of early death in end-stage renal disease patients starting dialysis. Am J 
Kidney Dis 29:2I4-222, 1997 
I49. Lowrie EG, Huang WH, Lew NL: Death risk predictors among peritoneal dialysis 
and hemodialysis patients: a preliminary comparison. Am J Kidney Dis 26:220-
228, I995 
I 50. Clase CM, StPierre MW, Churchill DN: Conversion between bromcresol green-
and bromcresol purple-measured albumin in renal disease. Nephrol Dial 
Transplant 16:1925-1929, 200I 
151. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum 
creatinine. Nephron I6:3 I-41 , 1976 
I 52. Levey AS, Green TG, Kusek JW, Beck GL: Modification of Diet in Renal 
Disease Study Group: A simplified equation to predict glomerular filtration rate 
from serum creatinine. JAm Soc Nephrol II :A0828 (abstract), 2000 
I 53. Khan IH, Campbell MK, Cantarovich D, Catto GR, Delcroix C, Edward N, 
Fontenaille C, Fleming L W, Gerlag PG, van Hamersvelt HW, Henderson IS, 
Koene RA, Papadimitriou M, Ritz E, Russell IT, Stier E, Tsakiris D, MacLeod 
AM: Survival on renal replacement therapy in Europe: is there a 'centre effect'? 
Nephrol Dial Transplant 11:300-307, I996 
154. Khan IH, Campbell MK, Cantarovich D, Catto GR, Delcroix C, Edward N, 
Fontenaille C, van Hamersvelt HW, Henderson IS, Koene RA, Papadimitriou M, 
Ritz E, Ramsay C, Tsakiris D, MacLeod AM: Comparing outcomes in renal 
replacement therapy: how should we correct for case mix? Am J Kidney Dis 
31:473-478, 1998 
155. Dialysis and Renal Transplantation, in Volume 1: CORR- Canadian Organ 
Replacement Register 2001 Report, Ottawa, Ontario, Canadian Institute for 
Health Information, 200 I 
I 56. Valderrabano F, Golper T, Muirhead N, Ritz E, Levin A: Chronic kidney disease: 
why is current management uncoordinated and suboptimal? Nephrol Dial 
Transplant16 Suppl 7:61-64,2001 
I 57. Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin B, 
Hannedouche T: Abysmal prognosis of patients with type 2 diabetes entering 
dialysis. Nephrol Dial Transplant 14:129-136, 1999 
126 
158. Levin A: Prevalence of cardiovascular damage in early renal disease. Nephrol 
Dial Transplant 16 Supp12:7-11, 2001 
159. Khan IH, MacLeod AM: Towards cost-effective dialysis therapy in Europe: the 
need for a multidisciplinary approach. Nephrol Dial Transplant 12:2483-2485, 
1997 
160. Italian Registry of Dialysis and Transplantation, in http://www.sin-ridt.orglsin-
ridtlsin-ridt.org.htm (accessed January 2003), Societa Italiana di Nefrologia, 
2000 
161. Powe NR: Early referral in chronic kidney disease: an enormous opportunity for 
prevention. Am J Kidney Dis 41:505-507, 2003 
162. Schwab SJ: Improving access patency: pre-end-stage renal disease strategies. J 
Am Soc Nephrol9:S124-129, 1998 
163. Fink J, Blahut S, Reddy M, Light P: Use of erythropoietin before the initiation of 
dialysis and its impact on mortality. Am J Kidney Dis 37:348-355,2001 
164. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA: Cardiac risk factors 
and the use of cardioprotective medications in patients with chronic renal 
insufficiency. Am J Kidney Dis 37:484-489, 2001 
165. Canadian Institute for Health Information (CIHI): Treatment of End-Stage Organ 
Failure in Canada, 1995 to 2004 (2006 Annual Report), in, 2006 
166. USRDS: the United States Renal Data System. Am J Kidney Dis 42:1-230, 2003 
167. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease 
and the risks of death, cardiovascular events, and hospitalization. N Eng! J Med 
351:1296-1305,2004 
168. Barrett BJ: Applying multiple interventions in chronic kidney disease. Semin Dial 
16:157-164,2003 
169. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, 
Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death 
in incident dialysis patients: a longitudinal study. Kidney Int 70:351-357, 2006 
170. Khan SS, Xue JL, Kazmi WH, Gilbertson DT, Obrador GT, Pereira BJ, Collins 
AJ: Does predialysis nephrology care influence patient survival after initiation of 
dialysis? Kidney Int 67: 103 8-1 046, 2005 
171. Goldstein M, Yassa T, Dacouris N, McFarlane P: Multidisciplinary predialysis 
care and morbidity and mortality of patients on dialysis. Am J Kidney Dis 44:706-
714,2004 
172. Thanamayooran S, Rose C, Hirsch DJ: Effectiveness of a multidisciplinary kidney 
disease clinic in achieving treatment guideline targets. Nephrol Dial Transplant 
20:2385-2393, 2005 
173. Hemmelgarn BR, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Walsh M, 
Culleton BF: Association between multidisciplinary care and survival for elderly 
patients with chronic kidney disease. JAm Soc Nephrol 18:993-999, 2007 
174. Nissenson AR, Agarwal R, Allon M, Cheung AK, Clark W, Depner T, Diaz-Buxo 
JA, Kjellstrand C, Kliger A, Martin KJ, Norris K, Ward R, Wish J: Improving 
outcomes in CKD and ESRD patients: carrying the torch from training to practice. 
Semin Dia/17:380-397, 2004 
127 
175. Kausz AT, Khan SS, Abichandani R, Kazmi WH, Obrador GT, Ruthazer R, 
Pereira BJ: Management of patients with chronic renal insufficiency in the 
Northeastern United States. JAm Soc Nephro/12:1501-1507, 2001 
176. Schwenger V, Ritz E: Audit of antihypertensive treatment in patients with renal 
failure. Nephrol Dial Transplan/13:3091-3095 , 1998 
177. Levin A, Stevens L, McCullough PA: Cardiovascular disease and the kidney. 
Tracking a killer in chronic kidney disease. Postgrad Med 111 :53-60, 2002 
178. McCullough PA: Evaluation and treatment of coronary artery disease in patients 
with end-stage renal disease. Kidney lnt Suppl:S51-58, 2005 
179. Chen RA, ScottS, Mattern WD, Mohini R, Nissenson AR: The case for disease 
management in chronic kidney disease. Dis Manag 9:86-92, 2006 
180. Mendelssohn DC, Toffelmire EB, Levin A: Attitudes of Canadian nephrologists 
toward multidisciplinary team-based CKD clinic care. Am J Kidney Dis 47:277-
284, 2006 
181. Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, 
Klarenbach S, Hemmelgarn BR: NSAID use and progression of chronic kidney 
disease. Am J Med 120:280 e281-287, 2007 
128 




